natriuretic peptide, brain profile

Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	53325981
MeSH ID	M0029829

Synonym
l-seryl-l-prolyl-l-lysyl-l-methionyl-l-valyl-l-glutaminylglycyl-l-serylglycyl-l-cysteinyl-l-phenylalanylglycyl-l-arginyl-l-lysyl-l-methionyl-l-aspartyl-l-arginyl-l-isoleucyl-l-seryl-l-seryl-l-seryl-l-serylglycyl-l-leucylglycyl-l-cysteinyl-l-lysyl-l-valyl-
human brain natriuretic factor-32
natriuretic factor-32 (human brain clone lambdahbnp57)
l-histidine, l-seryl-l-prolyl-l-lysyl-l-methionyl-l-valyl-l-glutaminylglycyl-l-serylglycyl-l-cysteinyl-l-phenylalanylglycyl-l_arginyl-l-lysyl-l-methionyl-l-alpha-aspartyl-l-arginyl-l-isoleucyl-l-seryl-l-seryl-l-seryl-l-serylglycyl-l-leucylglycyl-l-cystein
natriuretic factor-32 (human brain clone lambda hbnp57)
brain natriuretic peptide-32 (human)
nesiritide [usan:inn]
natriuretic peptide type-b
human brain natriuretic peptide-32
natriuretic peptide, brain
natriuretic factor, brain
1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecaazacyclotripentacontane, cyclic peptide deriv.
unii-p7wi8ul647
p7wi8ul647 ,
brain natriuretic factor
b-tye natriuretic peptide
07y2v56iup ,
unii-07y2v56iup
bnp (1-32), human
DTXSID101026612

Excerpt	Reference	Relevance
" Nesiritide is an attractive therapeutic option because of its more rapid and sustained hemodynamic profile with less adverse effects than alternative heart failure treatments, such as nitroglycerine or dobutamine."	( Nesiritide: practical guide to its safe and effective use. Fonarow, GC, 2001)	0.31
" Adverse effects for nesiritide are generally lower than for other vasoactive agents used for heart failure."	( Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Emerman, CL, 2002)	0.31
"In patients with RI, nesiritide was safe and improved haemodynamics and dyspnoea."	( The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Butler, J; Emerman, C; Mathur, VS; Peacock, WF; Young, JB, 2004)	0.32
"Nesiritide is as safe as NTG in heart failure patients with acute coronary syndromes."	( Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. Emerman, CL; Peacock, WF; Young, J, 2004)	0.32
" A totalof 1,645 nesiritide infusions was administered; 11 (< 1%) were discontinued due to an adverse event."	( Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Berkowitz, RL; Bertolet, B; Burnham, K; Horton, DP; Oren, RM; Saltzberg, MT; Silver, MA; Vijayaraghavan, K; Walker, K; Yancy, CW, 2004)	0.32
" The clinical importance of this research is the life prolongation effect of the treatment, which allows the late-appearing toxic cardiomyopathy, resulting in congestive heart failure and increasing mortality."	( [Cardiotoxicity induced by chemotherapy: possibilities of diagnosis]. Forster, T; Nagy, AC; Nagykálnai, T; Tolnay, E, 2004)	0.32
" Repeated sauna bathing was safely completed without any adverse effects in all patients."	( Safety and efficacy of repeated sauna bathing in patients with chronic systolic heart failure: a preliminary report. Imaizumi, T; Kai, H; Matsumoto, A; Miyamoto, H; Mizuta, Y; Nakaura, H; Osada, K, 2005)	0.33
"Repeated 60 degrees C sauna bathing was safe and improved symptoms and exercise tolerance in chronic CHF patients."	( Safety and efficacy of repeated sauna bathing in patients with chronic systolic heart failure: a preliminary report. Imaizumi, T; Kai, H; Matsumoto, A; Miyamoto, H; Mizuta, Y; Nakaura, H; Osada, K, 2005)	0.33
" Two of 204 infusions resulted in symptomatic hypotension, and there were no adverse renal events."	( Safety and tolerability of serial home infusions of nesiritide for advanced heart failure. Atkinson, J; Chung, ES; Daly, KA; Ibanez, K; Kereiakes, DJ; Menon, SG; Peterson, T; Robertson, R, 2006)	0.33
" Age-related plasma brain natriuretic peptide levels increased at 24 hours after ALB but did not predict cardiac adverse events."	( The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Ginsberg, MD; Hill, MD; Palesch, YY; Ryckborst, KJ; Tamariz, D, 2006)	0.33
"Cardiac troponin T (cTnT), high sensitivity C-reactive protein (hs-CRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have emerged as strong predictors of adverse events among patients presenting with acute coronary syndromes (ACS)."	( A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes. Cameron, SJ; Green, GB; Laterza, OF; Shah, S; Sokoll, LJ, 2007)	0.34
" Adverse events (AEs) occurring within 30 days (death, myocardial infarction, unstable angina and the need for revascularization procedures) were recorded and ROC curves were constructed."	( A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes. Cameron, SJ; Green, GB; Laterza, OF; Shah, S; Sokoll, LJ, 2007)	0.34
" Early detection of adverse effects of anthracyclines is therefore very important for proper prevention of congestive heart failure."	( [Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines]. Jackowska, T; Wasilewski, R, )	0.13
" Aggressive treatment of decompensated heart failure is associated with improved outcomes; however, therapies must be tailored to the presenting characteristics of each patient and most carry a risk of adverse events stemming from the pharmaceutical itself."	( Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trials. Abraham, WT; Hiestand, B, 2007)	0.34
" Patients were also monitored for adverse effects."	( Efficacy and safety of torasemide in children with heart failure. Ishido, H; Kamiyama, M; Katogi, T; Kobayashi, T; Kyo, S; Masutani, S; Senzaki, H; Taketazu, M, 2008)	0.35
" Serum concentrations of sodium and uric acid had not changed after torasemide treatment, and there were no serious adverse events that necessitated drug withdrawal."	( Efficacy and safety of torasemide in children with heart failure. Ishido, H; Kamiyama, M; Katogi, T; Kobayashi, T; Kyo, S; Masutani, S; Senzaki, H; Taketazu, M, 2008)	0.35
"we investigated whether higher concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) predicts cardiovascular adverse events (CV-AEs) in patients with osteoarthritis treated with antiinflammatory drugs."	( N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial. Brune, K; Giannitsis, E; Jaffe, AS; Katus, HA; Moecks, J; Spanuth, E, 2008)	0.35
" TRT, the delivery of therapeutic agents directly to the kidneys by renal arterial infusion, has the advantage of providing a higher local effective dose with potentially greater renal effects, while limiting systemic adverse effects due to renal first-pass elimination."	( Safety and performance of targeted renal therapy: the Be-RITe! Registry. Allie, DE; Cohen, MG; Danna, P; Fearon, WF; Filby, SJ; Findeiss, L; Kyriazis, D; Leon, MB; Mehran, R; Moses, JW; Price, MJ; Sachdev, N; Teirstein, PS; Vora, K; Walker, CM; Weinstock, BS; Weisz, G; Wiechmann, BN, 2009)	0.35
"Relaxin was safe and well-tolerated in patients with stable HF, and preliminary pharmacodynamic responses suggest it causes vasodilation."	( Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. Baumann, G; Boehmer, J; Dschietzig, T; Richter, C; Stangl, K; Teichman, S; Unemori, E; Wood, S, 2009)	0.35
" Adverse events were similar between groups; nesiritide was associated with more hypotension but less predefined worsening renal function."	( Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Cheng, M; Evans, R; Kim, SS; Krum, H; Massie, BM; Silver, MA; Stevenson, LW; Yancy, CW, 2008)	0.35
" Previous therapies that focused on increased inotropy have generally failed to improve symptoms without adverse consequences."	( Efficacy and safety of nesiritide in patients with acute decompensated heart failure. DeWald, TA; Hernandez, AF, 2010)	0.36
" The negative predictive value of the combined measure for long-term adverse events was 94%."	( Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients: a multi-marker approach with high-negative predictive value to rule out long-term adverse events. Boudoulas, H; Chalikias, GK; Chatzikyriakou, SV; Konstantinides, S; Lantzouraki, A; Mitrousi, K; Papazoglou, D; Stakos, D; Thomaidi, A; Tziakas, DN, 2012)	0.38
"001) for predicting future adverse events."	( In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Ballarino, P; Bertazzoni, G; Carpinteri, G; Clopton, P; Di Somma, S; Ferri, E; Magrini, L; Maisel, A; Marino, R; Mastrantuono, A; Mulè, P; Pazzaglia, M; Pittoni, V; Semplicini, A; Shah, K, 2010)	0.36
" The results indicate that intracoronary injection of allogenic multipotent stromal precursors is a safe procedure."	( Safety and efficiency of transplantation of allogenic multipotent stromal cells in surgical treatment of dilatated cardiomyopathy. Bochkov, NP; D'yachkov, AV; Fatkhutdinov, TKh; Goldstein, DV; Koroteyev, AV, 2010)	0.36
" No serious adverse event was observed."	( Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R, 2011)	0.37
" We evaluated the incidence of adverse events among an elderly population of trastuzumab-treated HER-2-positive breast cancer patients in adjuvant settings."	( Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Horio, A; Mizuno, T; Mukai, H; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Watanabe, T; Yamamoto, Y, 2012)	0.38
" Adverse events occurred in 11 patients (28."	( Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study. Horio, A; Mizuno, T; Mukai, H; Nakayama, T; Ohashi, Y; Sawaki, M; Taira, N; Tokudome, N; Uemura, Y; Watanabe, T; Yamamoto, Y, 2012)	0.38
"The clinical application of intravenous rhBNP is safe and effective for treatment of acute decompensated heart failure and acute exacerbation of chronic heart failure in this large patient cohort."	( [Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: a multicenter, randomized, open label, controlled study]. Hu, DY, 2011)	0.37
" Previous studies are of limited value due to their focus on adverse clinical events within several months after diagnosis of PE."	( A prognostic model for short term adverse events in normotensive patients with pulmonary embolism. Agterof, MJ; Biesma, DH; Eijkemans, MJ; Moumli, N; Schutgens, RE; Tromp, EA; van der Griend, R, 2011)	0.37
"The most severe side effect in breast cancer patients, treated with chemotherapy and/or radiotherapy is cardiotoxicity, leading to chronic heart failure and worsening the quality of life."	( Myocardial scintigraphy, echocardiography and proBNP for early detection of myocardial cardiotoxicity in breast cancer patients after chemo-radiotherapy. Atanasova, M; Chakarova, A; Piperkova, E; Tzonevska, A; Tzvetkov, K, )	0.13
" Treatment with bosentan is both safe and effective in patients with both simple and complex forms of ES."	( Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome. Aboulhosn, J; Houser, L; Miner, P; Williams, R, )	0.13
"Nesiritide resulted in improvements in dyspnea and edema, and similar adverse effects compared with conventional treatment."	( Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure. Bai, Y; Fu, S; Luo, L; Wang, H; Wang, L; Ye, P; Yi, S; Zhu, B, 2012)	0.38
"Doxorubicin [(DOX) Adriamycin] is an effective anticancer agent whose major limiting side effect is cardiotoxicity."	( Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats. Alsaad, AM; El-Kadi, AO; El-Sherbeni, AA; Zordoky, BN, 2012)	0.38
" The primary safety end point was a major adverse cardiac event."	( An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Aras, R; Clemens, R; Farr, M; Losordo, DW; Mendelsohn, FO; Pastore, J; Penn, MS; Rouy, D; Schaer, GL; Sherman, W, 2013)	0.39
" However, it is feared that an intensified, NT-proBNP-guided therapy carries a risk of adverse effects."	( Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. Brunner-La Rocca, HP; Erne, P; Estlinbaum, W; Kiencke, S; Maeder, M; Mayer, K; Muzzarelli, S; Neuhaus, M; Pfisterer, ME; Sanders-van Wijk, S; Tobler, D, 2013)	0.39
" All adverse events (AEs) were recorded during the 18-month trial period."	( Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. Brunner-La Rocca, HP; Erne, P; Estlinbaum, W; Kiencke, S; Maeder, M; Mayer, K; Muzzarelli, S; Neuhaus, M; Pfisterer, ME; Sanders-van Wijk, S; Tobler, D, 2013)	0.39
"NT-proBNP-guided therapy is safe in elderly and highly co-morbid HF patients."	( Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF. Brunner-La Rocca, HP; Erne, P; Estlinbaum, W; Kiencke, S; Maeder, M; Mayer, K; Muzzarelli, S; Neuhaus, M; Pfisterer, ME; Sanders-van Wijk, S; Tobler, D, 2013)	0.39
" Adverse events related to BAY 94-8862 were infrequent and mostly mild."	( Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Filippatos, G; Gheorghiade, M; Kim, SY; Kober, L; Kolkhof, P; Krum, H; Nowack, C; Pitt, B; Ponikowski, P; Zannad, F, 2013)	0.39
" Patient-reported adverse events included headache (4%) and heartburn (2%)."	( Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Doran, AK; Hill, W; Shapiro, S; Traiger, G; Zhang, L, 2013)	0.39
"The main objective of this study was to investigate whether cardiac troponin (cTn) and N-terminal, protein B-type natriuretic peptide (NT-proBNP) can be useful as indicators for amitriptyline cardiotoxicity which is a known drug having sublethal toxic cardiac effects."	( Cardiac troponin T and NT-proBNP as biomarkers of early myocardial damage in amitriptyline-induced cardiovascular toxicity in rats. Jaba, IM; Sava, A; Sorodoc, L; Sorodoc, V; Ungureanu, D, )	0.13
" No decrease of LVEF, increase of serum brain natriuretic peptide or any other adverse events were reported."	( Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2- positive breast cancer patients. Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Tomida, K; Umeda, T; Yamazaki, K, 2013)	0.39
"Intravenous infusion of TRS with 100 ml saline over 30 minutes in breast cancer patients can be considered safe based on results from the study."	( Safety assessment of intravenous administration of trastuzumab in 100ml saline for the treatment of HER2- positive breast cancer patients. Abe, H; Kawai, Y; Kubota, Y; Mori, T; Tani, T; Tomida, K; Umeda, T; Yamazaki, K, 2013)	0.39
" We conclude that with appropriate patient selection and a risk-adapted treatment approach, HDM/SCT is safe and effective in patients with AL amyloidosis and cardiac involvement."	( Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Berk, JL; Doros, G; Girnius, S; Meier-Ewert, HK; Quillen, K; Ruberg, FL; Sanchorawala, V; Seldin, DC; Sloan, JM, 2014)	0.4
"It is unclear whether adaptive servo-ventilation (ASV) is safe and effective in patients with severe systolic heart failure (HF)."	( Safety and efficacy of adaptive servo-ventilation in patients with severe systolic heart failure. Kurabayashi, M; Takama, N, 2014)	0.4
"Our study demonstrated that ASV therapy is safe and effective for use in very severe systolic HF patients as well as in relatively mild systolic HF patients."	( Safety and efficacy of adaptive servo-ventilation in patients with severe systolic heart failure. Kurabayashi, M; Takama, N, 2014)	0.4
"Cardiotoxicity is a dose-limiting side-effect of cancer chemotherapeutics such as anthracyclines."	( BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography. Hasbak, P; Kjaer, A; Skovgaard, D, 2014)	0.4
"The results of our study confirm that MTX therapy is safe for carefully selected and closely monitored MS patients."	( The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014)	0.4
" Our aim was to evaluate the use of the 5-point Likert scale for dyspnea to assess the degree of pulmonary congestion and to determine the prognostic value of this scale for predicting adverse events in heart failure outpatients."	( The five-point Likert scale for dyspnea can properly assess the degree of pulmonary congestion and predict adverse events in heart failure outpatients. Kalil, RA; Leiria, TL; Miglioranza, MH; Moraes, MA; Rover, MM; Sant'anna, RT; Weber, CK, 2014)	0.4
" The patients were then assessed every 30 days during follow-up to identify adverse clinical outcomes."	( The five-point Likert scale for dyspnea can properly assess the degree of pulmonary congestion and predict adverse events in heart failure outpatients. Kalil, RA; Leiria, TL; Miglioranza, MH; Moraes, MA; Rover, MM; Sant'anna, RT; Weber, CK, 2014)	0.4
"In our series, higher baseline scores on the 5-point Likert scale were related to pulmonary congestion and were independently associated with adverse events during follow-up."	( The five-point Likert scale for dyspnea can properly assess the degree of pulmonary congestion and predict adverse events in heart failure outpatients. Kalil, RA; Leiria, TL; Miglioranza, MH; Moraes, MA; Rover, MM; Sant'anna, RT; Weber, CK, 2014)	0.4
" No significant differences were found in terms of safety and feasibility between the different delivery routes, with no significant difference in procedural complications or major adverse cardiac events."	( Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study. Agrawal, S; Ako, E; Archbold, RA; Arnous, S; Brookman, P; Locca, D; Martin, J; Mathur, A; Mills, P; Mozid, A; Rothman, M; Saunders, N; Yeo, C, 2014)	0.4
"Peripheral mobilization of BMSCs with or without subsequent direct myocardial delivery appears safe and feasible in patients with chronic ischemic heart failure."	( Safety and feasibility of intramyocardial versus intracoronary delivery of autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot study. Agrawal, S; Ako, E; Archbold, RA; Arnous, S; Brookman, P; Locca, D; Martin, J; Mathur, A; Mills, P; Mozid, A; Rothman, M; Saunders, N; Yeo, C, 2014)	0.4
"26) was consistently high irrespective of LVEF, and there was no major exercise-related adverse event."	( Targeting of high peak respiratory exchange ratio is safe and enhances the prognostic power of peak oxygen uptake for heart failure patients. Arakawa, T; Goto, Y; Kumasaka, R; Nakanishi, M; Noguchi, T; Sugimachi, M; Takaki, H, 2014)	0.4
"The purpose of this study was to investigate the predictive values of baseline and changes in cystatin C (CysC) and its derived equations for short-term adverse outcomes and the effect of nesiritide therapy on CysC in acute decompensated heart failure (ADHF)."	( Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. Anker, SD; Armstrong, PW; Butler, J; Califf, RM; Dupont, M; Felker, GM; Gottlieb, SS; Hernandez, AF; Hsu, AP; Massie, BM; McMurray, JJ; Metra, M; O'Connor, CM; Starling, RC; Tang, WHW; Troughton, RW; Voors, AA, 2015)	0.42
" Higher baseline (but not follow-up) CysC levels were associated with increased risk of 30-day adverse events and less improvement in dyspnea after 24 h as well as 180-day mortality, although not incremental to blood urea nitrogen."	( Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. Anker, SD; Armstrong, PW; Butler, J; Califf, RM; Dupont, M; Felker, GM; Gottlieb, SS; Hernandez, AF; Hsu, AP; Massie, BM; McMurray, JJ; Metra, M; O'Connor, CM; Starling, RC; Tang, WHW; Troughton, RW; Voors, AA, 2015)	0.42
" However, worsening renal function based on CysC rise was not predictive of adverse events."	( Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. Anker, SD; Armstrong, PW; Butler, J; Califf, RM; Dupont, M; Felker, GM; Gottlieb, SS; Hernandez, AF; Hsu, AP; Massie, BM; McMurray, JJ; Metra, M; O'Connor, CM; Starling, RC; Tang, WHW; Troughton, RW; Voors, AA, 2015)	0.42
"Serious adverse events (SAEs) from heart failure (HF) therapy are frequent; however, techniques to identify at-risk patients are inadequate."	( Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study. Belcher, AM; Gaggin, HK; Gandhi, PU; Januzzi, JL; Motiwala, SR; Szymonifka, J, 2015)	0.42
" With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group."	( Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015)	0.42
"5 (3-33) months follow-up cardiac adverse events occurred in 5 (9."	( The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Akbulut, H; Demirkazık, A; İçli, F; Onur, H; Oztuna, DG; Şenler, FC; Ürun, Y; Utkan, G; Yalcin, B, 2015)	0.42
" This is a significant limitation because sustained changes in blood pressure are often accompanied by changes in heart rate and together can lead to cardiac hypertrophy and myocardial degeneration in animals, and major adverse cardiovascular events (MACE) in humans."	( Natriuretic Peptides as Cardiovascular Safety Biomarkers in Rats: Comparison With Blood Pressure, Heart Rate, and Heart Weight. Engle, SK; Watson, DE, 2016)	0.43
" However, it increased the risk of cardiovascular adverse events."	( Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials. Gong, B; Li, Z; Wu, Z, 2016)	0.43
"3 days, adverse events occurred during follow up in 17 % of cases."	( Carbohydrate-antigen-125 levels predict hospital stay duration and adverse events at long-term follow-up in Takotsubo cardiomyopathy. Brunetti, ND; Di Biase, M; Di Martino, L; Ferraretti, A; Ieva, R; Musaico, F; Santoro, F; Tarantino, N, 2016)	0.43
" The primary endpoint was 30-day adverse outcome defined as PE- or bleeding-related mortality, cardiopulmonary resuscitation, or intensive care unit admission."	( Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. Brouwer, RE; de Vreede, MJ; den Exter, PL; Dolsma, J; Eijsvogel, M; Faber, LM; Grootenboers, MJ; Heller-Baan, R; Hovens, MM; Huisman, MV; Jonkers, GJ; Klok, FA; Melissant, CF; Peltenburg, H; Post, JP; van de Ree, MA; van Gerwen, M; van Kralingen, KW; Vlasveld, LT; Zondag, W, 2016)	0.43
"Outpatient treatment of patients with PE selected on the basis of the Hestia criteria alone was associated with a low risk of adverse events."	( Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. Brouwer, RE; de Vreede, MJ; den Exter, PL; Dolsma, J; Eijsvogel, M; Faber, LM; Grootenboers, MJ; Heller-Baan, R; Hovens, MM; Huisman, MV; Jonkers, GJ; Klok, FA; Melissant, CF; Peltenburg, H; Post, JP; van de Ree, MA; van Gerwen, M; van Kralingen, KW; Vlasveld, LT; Zondag, W, 2016)	0.43
"The sarcopenia screening test can be used to predict future adverse events in patients with HF."	( A simple sarcopenia screening test predicts future adverse events in patients with heart failure. Araki, S; Hanatani, S; Hokimoto, S; Izumiya, Y; Kaikita, K; Kimura, Y; Kojima, S; Onoue, Y; Sakamoto, K; Tanaka, T; Tsujita, K; Yamamoto, E; Yamamura, S; Yamamuro, M, 2016)	0.43
"Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended."	( A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients. Blagus, R; Jug, B; Matos, E; Zakotnik, B, 2016)	0.43
"To investigate the effect of proteinuria on in-hospital severe adverse events and prognosis of the patients with heart failure(HF)."	( [Predictive value of proteinuria for in-hospital severe adverse events and prognosis of the patients with heart failure]. He, KR; Huang, C; Li, ZL; Liang, XL; Liu, X; Zeng, WX; Zhen, XF, 2016)	0.43
" Univariate and multivariate Logistic regression analysis were used to evaluate the correlations of proteinuria with in-hospital adverse events and prognosis."	( [Predictive value of proteinuria for in-hospital severe adverse events and prognosis of the patients with heart failure]. He, KR; Huang, C; Li, ZL; Liang, XL; Liu, X; Zeng, WX; Zhen, XF, 2016)	0.43
" Proteinuria should be a potential marker for in-hospital adverse events and prognosis of severe hospitalized HF patients."	( [Predictive value of proteinuria for in-hospital severe adverse events and prognosis of the patients with heart failure]. He, KR; Huang, C; Li, ZL; Liang, XL; Liu, X; Zeng, WX; Zhen, XF, 2016)	0.43
" Patients given urapidil had fewer associated adverse events, specifically headache (p=0."	( Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017)	0.46
"Intravenous administration of urapidil, compared with nitroglycerin, was associated with better control of blood pressure and preserved cardiac function, as well as fewer adverse events, for elderly patients with hypertension and acute heart failure."	( Efficacy and Safety of Intravenous Urapidil for Older Hypertensive Patients with Acute Heart Failure: A Multicenter Randomized Controlled Trial. Chen, XM; Fu, Y; Guo, JC; He, JY; Hua, Q; Li, J; Qin, J; Qin, S; Wang, Z; Yang, W; Zhan, H; Zhou, YJ, 2017)	0.46
" Major adverse clinical events that would potentially halt testing were pre-defined."	( Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease. Oyama, MA; Solter, PF; Stern, JA; Thorn, CL, 2017)	0.46
" The rhBNP is effective and safe for the treatment of cardiac insufficiency."	( [Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with severe heart failure: a prospective multicenter clinical study]. Feng, X; Meng, Y; Wei, Y; Wu, Y, 2017)	0.46
"To investigate the effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with coronary heart disease."	( [Effects of dexmedetomidine on perioperative cardiac adverse events in elderly patients with  coronary heart disease]. Han, D; Shen, J; Sun, Y; Zhao, W; Zhu, K, 2017)	0.46
" Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF."	( Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. Anstrom, KJ; Braunwald, E; Butler, J; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Kalogeropoulos, AP; Konstam, MA; Mann, DL; Margulies, KB; McNulty, SE; Mentz, RJ; Redfield, MM; Shah, M; Tang, WHW; Whellan, DJ, 2017)	0.46
" Given the current lack of biomarkers in HF with preserved ejection fraction (HFpEF), we aimed to investigate the prognostic performance of the newly developed high-sensitivity (hs) assays for cardiac troponin I (hsTnI) compared with troponin T (hsTnT) for adverse events in HFpEF vs."	( The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Chong, JPC; de Kleijn, DPV; den Ruijter, H; Gohar, A; Jaufeerally, F; Lam, CSP; Leong, GKT; Liew, OW; Ling, LH; Ong, HY; Richards, AM; Sim, D; Yeo, DPS, 2017)	0.46
" During follow-up for a period of 275 person-years, 50 adverse events were recorded."	( Parathyroid hormone, calcidiol, calcitriol and adverse events in the acute coronary syndrome. Castañeda Sancirilo, M; Castillo Moreno, JA; Clavel Ruipérez, G; Consuegra Sánchez, L; García de Guadiana Romualdo, L; García Escribano, I; Jaulent Huertas, L; Martínez Díaz, JJ; Merelo Nicolás, M; Ramos Ruiz, P; Soria Arcos, F; Wasniewski, S, 2018)	0.48
" The primary outcomes include major adverse cardiovascular events (including angina, acute myocardial infarction, pulmonary embolism and aortic dissection)."	( Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial. Gao, J; Li, J; Li, Y; Tian, PP, 2018)	0.48
" Eligible RCTs were included that reported mortality, the change of EuroQol Group 5-Dmensional Self-report Questionnaire (EQ-5D) US index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), or serious adverse events (SAEs)."	( The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. Huang, J; Xiong, B; Zheng, W; Zheng, X, 2018)	0.48
" The underlying mechanism of these adverse cardiac effects is largely unknown."	( Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Becker, JR; Force, T; Galindo, CL; Glennon, MS; Gupte, M; Lal, H; Singh, AP; Umbarkar, P; Zhang, Q, 2019)	0.51
" Compared with spironolactone and eplerenone, finerenone 10 mg was associated with low risk in the occurrence of cardiovascular mortality, hospitalization, and adverse events (P < 0."	( Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Chen, X; Shen, W; Wu, Q; Wu, T; Xu, G; Xu, X; Yang, P; Zhu, D, 2019)	0.51
"Cardiac dysfunction is a common adverse effect of trastuzumab."	( Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. Abdi, E; Asghari, R; Barry, W; Bastick, P; Beith, J; Bell, R; Chantrill, L; Goel, S; Guo, H; Harrison, M; Kiely, BE; Kohonen-Corish, M; Liu, J; Lynch, J; Murray, B; Rutovitz, J; Sullivan, A, 2019)	0.51
"STRONG-HF is the first study to assess whether rapid up-titration of evidence-based guideline-recommended therapies with close follow-up in a large cohort of patients discharged from an acute HF admission is safe and can affect adverse outcomes during the first 90 days after discharge."	( Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Addad, F; Celutkiene, J; Chioncel, O; Cotter, G; Damasceno, A; Davison, B; Diaz, R; Duengen, HD; Filippatos, G; Goncalvesova, E; Kimmoun, A; Mebazaa, A; Merai, I; Metra, M; Ponikowski, P; Privalov, D; Sani, MU; Shogenov, Z; Sliwa, K; Solal, AC; Takagi, K; Voors, AA, 2019)	0.51
"The use of PS, with either low or high inflation pressures, is safe and has no detrimental effects on hemodynamic parameters or BNP levels in patients with severely reduced LVEF following clinical stabilization and optimal medical therapy."	( The Safety and Hemodynamic Effects of Pneumatic Sleeves in Patients with Severe Left Ventricular Dysfunction. Atar, S; Bickel, A; Khader, M; Moady, G; Shturman, A, 2019)	0.51
" Whereas, several adverse events caused by SGLT2is were also reported."	( Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus. Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y, 2019)	0.51
"This prospective study aimed to evaluate the value of the cardiac cycle time-corrected electromechanical activation time (EMATc) measured at admission for predicting major cardiac adverse events (MACEs) in hospitalized patients with chronic heart failure (CHF)."	( Predictive Value of Electromechanical Activation Time for In-Hospital Major Cardiac Adverse Events in Heart Failure Patients. Liu, WX; Lyu, SZ; Zhang, J, 2020)	0.56
" Levosimendan is therefore effective and safe in the short-term treatment of chronic systolic heart failure."	( Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure. Bai, L; Cui, XR; Jia, M; Li, RB; Wang, D; Yang, XH; Zhang, JD, )	0.13
" Safety endpoints included time to clinical worsening and incidence of adverse events (AEs)."	( Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. Huo, Y; Ji, Q; Jing, ZC; Li, M; Li, Y; Liu, J; Wang, P; Wu, B; Yu, Z; Zeng, X; Zhang, G; Zhong, J; Zhu, P; Zhu, W, 2020)	0.56
" Adverse events were reported in 52 (73."	( Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. Huo, Y; Ji, Q; Jing, ZC; Li, M; Li, Y; Liu, J; Wang, P; Wu, B; Yu, Z; Zeng, X; Zhang, G; Zhong, J; Zhu, P; Zhu, W, 2020)	0.56
" We select literature according to prespecified inclusion and exclusion criteria and record data such as drug type, mortality, and adverse reactions."	( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock. Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020)	0.56
" Milrinone was most effective at reducing mortality and had the lowest incidence of adverse reactions."	( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock. Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020)	0.56
"This network meta-analysis demonstrated that milrinone was the most effective medication at reducing mortality and adverse events in patients suffering from cardiogenic shock."	( Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock. Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S, 2020)	0.56
" We assessed demographic, hemodynamic, and laboratory data, including BNP and hs-TnT levels, for the prediction of cardiac adverse events in 85 patients."	( Risk Factors for Cardiac Adverse Events in Infants and Children with Complex Heart Disease Scheduled for Bi-ventricular Repair: Prognostic Value of Pre-operative B-Type Natriuretic Peptide and High-Sensitivity Troponin T. Inoue, N; Kaneko, S; Mori, Y; Murakami, T; Nakashima, Y, 2020)	0.56
" Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority."	( NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Blancas, I; Garrido, JM; Martín-Pérez, FJ; Rodríguez-Serrano, F, 2020)	0.56
" Early initiation during an acute heart failure (AHF) hospitalization may facilitate decongestion, improve natriuresis, and facilitate safe transition to a beneficial outpatient therapy for both diabetes and heart failure."	( Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB, 2021)	0.62
"The use of levosimendan was safe and associated with clinical improvement and reduction in BNP level in AdvHF patients hospitalized due to HF decompensation, although the mortality and re-hospitalization rate during the one-year follow-up remains high."	( Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure. Gruchała, M; Korościk, E; Lelonek, M; Stopczyńska, I; Straburzyńska-Migaj, E, 2020)	0.56
"Breast cancer treatment is associated with the occurrence of various cardiac adverse events."	( Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients. Dolžan, V; Goričar, K; Marinko, T; Stojanov Konda, JT, 2020)	0.56
"Myocardial toxicity is a common side effect of doxorubicin (DOXO) therapy in breast cancer patients."	( Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study. Alves, MT; de Oliveira, AN; Gomes, KB; Oliveira, HHM; Pestana, RMC; Sabino, AP; Silva, LM; Simões, R; Soares, CE, 2022)	0.72
"Improvements in cancer survival have led to the emergence of cardiovascular disease as an important determinant of adverse outcome in survivors."	( Circulating Biomarkers for Cardiotoxicity Risk Prediction. Akhter, N; Cascino, GJ; Gong, FF; Murtagh, G, 2021)	0.62
" Dyspnoea severity, the ratio of E to e' (E/e'), the incidence of side effects and adverse events, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, left ventricular ejection fraction (LVEF; left ventricular systolic function) before discharge, average length of hospitalisation, LVEF and soluble suppression of tumorigenicity-2 (sST2) at 3 months after discharge, incidence of major adverse cardiac and cerebrovascular events (MACCE) and readmission rate within 3 months were recorded and compared between the two groups."	( Effectiveness and Safety of Intravenous Nicorandil Application in Patients With Acute Heart Failure With Low Baseline Blood Pressure. Cai, Z; Ke, S; Ke, X; Qiu, W; Wu, Y; Zhang, Y, 2022)	0.72
"Background Assessing the risk of serious adverse events (SAEs) during hypertension treatment is important for understanding the benefit-harm trade-offs of lower blood pressure goals."	( Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT. Ambrosius, WT; Ascher, SB; Ballantyne, CM; Berry, JD; Bullen, AL; de Lemos, JA; Estrella, MM; Garimella, PS; Ix, JH; Jotwani, VK; Killeen, AA; Nambi, V; Scherzer, R; Shlipak, MG, 2022)	0.72
" Five serious adverse events (0."	( Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. Ahmed, R; Albert, NM; Allen, LA; Averina, V; Boehmer, JP; Chien, CV; Cowie, MR; Galvao, M; Hernandez, AF; Klein, L; Kwan, B; Lam, CSP; Ruble, SB; Stein, K; Stolen, CM, 2022)	0.72
" The potential risk factors for the discontinuation events caused by sac/val-related adverse events (AEs) were explored."	( Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C, 2022)	0.72
" Besides, statistics were made in terms of serum B-type natriuretic peptide (BNP), C-reactive protein (CRP) and mean arterial pressure (MAP) concentrations, time of asthma relief, heart rate recovery (HRR), edema resolution, and hospitalization, as well as incidence of adverse reactions (ARs)."	( Continuous Renal Replacement Therapy for Hypertension Complicated by Refractory Heart Failure: An Analysis of Safety and Nursing Highlights. Li, J; Zhang, M, 2022)	0.72
"In addition, no serious adverse effects associated with SMI were observed during the study period, thus suggesting that SMI is safe."	( Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials. Kong, Y; Liu, Q; Wang, D; Wang, Y; Zhong, G, 2023)	0.91
"In the present work, we provide evidence that combined SMI therapy is beneficial and safe for improving cardiac function in patients with DCM."	( Efficacy and safety evaluation of Shenmai injections for dilated cardiomyopathy: A systematic review and meta-analysis of randomised controlled trials. Kong, Y; Liu, Q; Wang, D; Wang, Y; Zhong, G, 2023)	0.91
" In terms of safety, the total adverse events in the combined group of ZYC were comparable to those in the conventional group, and TSA demonstrated that this result needed more research and demonstration."	( Efficacy and safety of Zhenyuan capsule in the treatment of chronic heart failure: A meta-analysis and trial sequential analysis. Liu, J; Zhang, Z, 2023)	0.91

Excerpt	Reference	Relevance
" These results suggest that clearance receptor is involved in the clearance of the physiological levels of alpha-rANP and that NEP plays a major role in the clearance of a pharmacological dose of alpha-rANP, at which clearance receptors are thought to be saturated, and also indicate a pharmacokinetic difference between alpha-rANP and rBNP."	( Clearance mechanisms of atrial and brain natriuretic peptides in rats. Hama, N; Hashimoto, Y; Hori, R; Imura, H; Mori, S; Nakao, K; Yamaguchi, M; Yasuhara, M, 1994)	0.29
" The population analysis was useful for analyzing such pharmacodynamic data for which the individual analysis could not be applied easily."	( Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats. Hama, N; Hashimoto, Y; Hori, R; Imura, H; Mori, S; Nakao, K; Yamaguchi, M; Yasuhara, M, 1993)	0.29
" The serum concentration of pertuzumab declined slowly (terminal half-life is approximately 3 weeks)."	( Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. Fujisaka, Y; Fujiwara, Y; Shimizu, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2009)	0.35
" We determined safety, tolerability, and pharmacodynamic effects of human Relaxin in stable HF."	( Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. Baumann, G; Boehmer, J; Dschietzig, T; Richter, C; Stangl, K; Teichman, S; Unemori, E; Wood, S, 2009)	0.35
"Relaxin was safe and well-tolerated in patients with stable HF, and preliminary pharmacodynamic responses suggest it causes vasodilation."	( Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. Baumann, G; Boehmer, J; Dschietzig, T; Richter, C; Stangl, K; Teichman, S; Unemori, E; Wood, S, 2009)	0.35
" HSA-(BNP)(2), derived from the joining of human BNP to the C-terminus of human serum albumin (HSA), has been developed to prolong the BNP pharmacodynamic action."	( A sandwich ELISA for assessment of pharmacokinetics of HSA-(BNP)2 fusion protein in mouse plasma. Chen, Y; Ding, YD; Jin, J; Lei, JY, 2010)	0.36
"This study sought to determine the pharmacodynamic effect of modulation of volume status by withdrawal and reinstitution of diuretic treatment on markers of renal and tubular function."	( Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. Collinson, PO; Damman, K; Gaze, D; Hillege, HL; Lip, GY; MacFadyen, RJ; Ng Kam Chuen, MJ; van Oeveren, W; van Veldhuisen, DJ; Voors, AA, 2011)	0.37
" The pharmacokinetic exposure of the LCZ696 analytes in patients with HF observed in this study is comparable to that observed in the pivotal Phase III study."	( Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I, 2016)	0.43
" Exposure to anthracycline and trastuzumab was simulated based on available dosing records and by using a kinetic-pharmacodynamic (K-PD) and a fixed pharmacokinetic (PK) model from literature, respectively."	( Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Boekhout, AH; Burylo, AM; de Vries Schultink, AHM; Dorlo, TPC; Gietema, JA; Huitema, ADR; Schellens, JHM; van Hasselt, JGC, 2018)	0.48
"The objective of this article was to characterize the pharmacokinetics and pharmacokinetic variability of vericiguat combined with guideline-directed medical therapy (standard of care), and identify exposure-response relationships for safety (hemodynamics) and pharmacodynamic markers of efficacy (N-terminal pro-B-type natriuretic peptide concentration [NT-proBNP]) in patients with heart failure and left ventricular ejection fraction < 45% in the SOCRATES-REDUCED study (NCT01951625)."	( Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Austin, R; Becker, C; Frei, M; Garmann, D; Grevel, J; Klein, D; Meyer, M; Pieske, B; Roessig, L; Ruehs, H, 2021)	0.62
" Pharmacokinetic (PK) data from the phase II trial SOCRATES-REDUCED (Soluble Guanylate Cyclase Stimulator in Heart Failure Study) and the phase III trial VICTORIA (Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction) were used to characterize vericiguat PK."	( Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. Armstrong, PW; Arrington, L; Becker, C; Blaustein, RO; Gheyas, F; Meyer, M; Passarell, J; Patel, Y; Trujillo, ME; Wenning, L, 2022)	0.72

Excerpt	Reference	Relevance
"The objective of this study is to determine the effect of nesiritide (human recombinant BNP [hBNP]) in combination with standard therapy on the concentrations of B-type natriuretic peptide (BNP) and N-terminal probrain natriuretic peptide (NT-proBNP)."	( Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Bhalla, V; Chiu, A; Clopton, P; Cremo, R; Fitzgerald, RL; Gardetto, N; Maisel, AS, 2005)	0.33
"Nesiritide, in combination with standard therapy, significantly lowered the endogenous concentrations of natriuretic peptides during infusion and after dosing was completed."	( Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Bhalla, V; Chiu, A; Clopton, P; Cremo, R; Fitzgerald, RL; Gardetto, N; Maisel, AS, 2005)	0.33
"This paper reports a miniaturized immunosensor designed to determine a trace level cardiac marker, B-type natriuretic peptide (BNP), using a microfluidic device combined with a portable surface plasmon resonance (SPR) sensor system."	( On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system. Kurita, R; Mizutani, F; Niwa, O; Sato, Y; Yokota, Y, 2006)	0.33
"TDI combined with pulsed-wave Doppler echocardiography predicted the LVEDP of VSD infants, whereas the plasma BNP value did not have a significant association with the LVEDP."	( Noninvasive estimation of left ventricular end-diastolic pressure using tissue Doppler imaging combined with pulsed-wave Doppler echocardiography in patients with ventricular septal defects: a comparison with the plasma levels of the B-type natriuretic Pe Aoki-Okazaki, M; Harada, K; Oyamada, J; Shimada, S; Takahashi, T; Tamura, M; Toyono, M, 2008)	0.35
"NT-proBNP is correlated with MVD severity and could be used in combination with clinical status to predict cardiac outcome."	( Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. Chetboul, V; Daste, T; Gouni, V; Hawa, G; Lefebvre, HP; Pouchelon, JL; Poujol, L; Sampedrano, CC; Serres, F; Tissier, R; Trumel, C, 2009)	0.35
" However, little evidence exists regarding the prognostic role of RV systolic and diastolic function indexes in combination with plasma B-type natriuretic peptide (BNP) in advanced CHF."	( Prognostic value of tissue Doppler right ventricular systolic and diastolic function indexes combined with plasma B-type natriuretic Peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Bistola, V; Filippatos, G; Flessas, N; Ikonomidis, I; Iliodromitis, E; Kremastinos, DT; Nikolaou, M; Panou, F; Paraskevaidis, I; Parissis, JT, 2010)	0.36
"We investigated the prognostic utility of changes in N-terminal pro-brain natriuretic peptide (NT-proBNP) in combination with Sequential Organ Failure Assessment (SOFA) score in patients with acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) concomitant with septic shock."	( Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Chang, J; Jung, JY; Kang, YA; Kim, EY; Kim, SK; Kim, YS; Lim, JE; Park, BH; Park, MS, 2011)	0.37
" We attempt to evaluate the prognostic potential of NT-proBNP in combination with the sequential organ failure assessment (SOFA) score in sepsis."	( Predictive value of N-terminal pro-brain natriuretic peptide in combination with the sequential organ failure assessment score in sepsis. He, YZ; Ju, MJ; Luo, Z; Tu, GW; Wu, ZG; Xue, ZG; Zhu, DM, 2012)	0.38
"The aim of this study was to investigate the effects of a noninvasive positive pressure ventilation therapy on cardiac structure and function in patients with coronary heart disease combined with obstructive sleep apnea/hypopnea syndrome (OSAHS)."	( Cardiac structure and function improvements in coronary artery disease combined with severe obstructive sleep apnea/hypopnea syndrome patients via noninvasive positive pressure ventilation therapy. Cao, G; Feng, L; Huang, H; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014)	0.4
"For patients with coronary heart disease combined with OSAHS, noninvasive mechanical ventilation therapy can significantly improve heart functions and reduce the occurrence of cardiovascular complications."	( Cardiac structure and function improvements in coronary artery disease combined with severe obstructive sleep apnea/hypopnea syndrome patients via noninvasive positive pressure ventilation therapy. Cao, G; Feng, L; Huang, H; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014)	0.4
"To study the protective effects of valsartan (Val) and benazepril, (Ben) combined with atorvastatin (Ato), on cardiorenal syndrome (CRS) in rats."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	0.42
"Valsartan and benazepril, combined with atorvastatin, can have significant protective effects on cardiorenal functions of rats with CRS, with no significant difference between these two drugs."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	0.42
"The aims to investigate the different protective effects of valsartan and benazepril when combined with atorvastatin in the cardio-renal functions of cardio-renal syndrome (CRS) patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	0.42
"When combined with atorvastatin, both valsartan and benazepril effectively improved the cardio-renal functions of early CRS patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	0.42
"In this small study, use of ADMA in combination with NT-proBNP produced excellent sensitivity and specificity for the non-invasive identification of SSc-PAH."	( The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Gabbay, E; Lester, S; Nash, P; Nikpour, M; Prior, D; Proudman, SM; Rabusa, C; Rischmueller, M; Roddy, J; Sahhar, J; Stevens, W; Thakkar, V; Walker, JG; Youssef, P; Zochling, J, )	0.13
"The patients were divided into three groups according to specific criteria: patients with AECOPD (group A), patients with COPD combined with CHD (group B), and patients with CHD (group C)."	( Vitamin D should be supplemented more actively in elderly patients with coronary heart disease combined with COPD. Yuan, QY; Zhang, L, 2016)	0.43
" The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of 100 mg/day spironolactone versus placebo (or continued low-dose spironolactone use in participants who are already receiving spironolactone at baseline) in 360 patients hospitalized for AHF."	( Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. Anstrom, KJ; Braunwald, E; Butler, J; Felker, GM; Hernandez, AF; Kalogeropoulos, A; Konstam, MA; Redfield, MM; Shah, MR; Tang, WH, 2016)	0.43
"Aim of the present study is to investigate the clinical efficacy of recombinant human brain natriuretic peptide (rhBNP) and dopamine combination treatment in patients with cardiorenal syndrome type 4 (CRS4) combined with hypotension."	( Clinical therapeutic strategy of recombinant human brain natriuretic peptide and dopamine in cardiorenal syndrome type 4 patients combined with hypotension. Han, B; Li, H; Ma, Q, 2017)	0.46
"To investigate the therapeutic strategy for the multiple ventricular septal defects (VSD) combined with a muscular ventricular septal defect (MVSD) in the infants and young children."	( Therapeutic strategy for multiple VSD combined with MVSD in infants and young children. Hu, YB; Liu, GY; Wang, L; Zou, JQ, 2017)	0.46
" This study explores if the Doppler myocardial performance (Tei) index combined with the plasma B-type natriuretic peptide (BNP) levels can assess cardiac function in patients with decompensated cirrhosis."	( Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis. An, XF; Han, C; Wang, LK; Wang, YC; Wu, XL; Yang, JL; Yang, RM; Zhang, SM, 2018)	0.48
" We aimed to test the long-term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure (ADHF)."	( Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Bae, MH; Chae, SC; Cho, HJ; Cho, Y; Jang, SY; Kim, CY; Kim, NK; Lee, JH; Park, HS; Roh, JH; Son, J; Yang, DH; Yoon, JY, 2019)	0.51
" Addition of CA-125 in combination with NT-proBNP and established risk factors further increased the predictive power for mortality in patients with ADHF."	( Serum levels of carbohydrate antigen 125 in combination with N-terminal pro-brain natriuretic peptide in patients with acute decompensated heart failure. Bae, MH; Chae, SC; Cho, HJ; Cho, Y; Jang, SY; Kim, CY; Kim, NK; Lee, JH; Park, HS; Roh, JH; Son, J; Yang, DH; Yoon, JY, 2019)	0.51
"This experiment aimed to study the effect of trimetazidine combined with perindopril on NT-proBNP levels in rats with dilated cardiomyopathy (DCM)."	( Effect of trimetazidine combined with perindopril on NT-proBNP level in rats with dilated cardiomyopathy. Chen, L; Lin, J; Yan, J; Zhong, B, 2020)	0.56
"This study aims to explore the clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and the effects on N terminal pro B type natriuretic peptide (NT-ProBNP) and creatine kinase-MB (CK-MB) levels."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	0.56
"Ticagrelor combined with aspirin has definite therapeutic effect on patients with coronary heart disease angina pectoris, with low prevalence of adverse reactions."	( Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020)	0.56
"The objective was to explore the value of serum carbohydrate antigen 125 (CA125) combined with N-terminal pro B-type natriuretic peptide (NT-proBNP) in predicting the clinical prognosis of patients with acute heart failure (AHF)."	( Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure. Chen, X; Huang, M; Wu, M; Xu, K; Zhuo, X, 2021)	0.62
"Elevated CA125 is an independent predictor of poor prognosis in patients with AHF, and combined with NT-proBNP can improve the efficiency of risk identification."	( Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure. Chen, X; Huang, M; Wu, M; Xu, K; Zhuo, X, 2021)	0.62
"In conclusion, cMRI in combination with echocardiography was sufficiently informative to follow-up this PVS patient both before and after BPV."	( Balloon Valvuloplasty to Treat Adult Symptomatic Pulmonary Valve Stenosis with Sequential Follow-Up Using Cardiac Magnetic Resonance Imaging in Combination with Echocardiography. Ando, J; Fujiwara, T; Inaba, T; Inuzuka, R; Ishii, S; Komuro, I; Takeda, N, 2020)	0.56
"To investigate the clinical effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures."	( Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures. Fu, M; Liu, Y; Wang, Z, 2020)	0.56
" Clinical manifestations; left ventricular ejection fraction (LVEF); left ventricular end-diastolic dimension (LVEDD); left ventricular end-systolic dimension (LVESD); B-type natriuretic peptide (BNP), superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), and endothelin-1 (ET-1) levels; and self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores were compared between before and after treatment to evaluate the curative effects of Xinkeshu combined with levosimendan."	( Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures. Fu, M; Liu, Y; Wang, Z, 2020)	0.56
"Levosimendan combined with Xinkeshu can improve cardiac function, alleviate oxidative stress, and relieve anxiety and depression in oldest-old patients with perioperative heart failure and hip fracture."	( Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures. Fu, M; Liu, Y; Wang, Z, 2020)	0.56
"The safety and efficacy of Naoxintong Capsules combined with Western medicine in treatment of chronic heart failure(CHF) were analyzed based on Meta-analysis system."	( [Meta-analysis of Naoxintong Capsules combined with Western medicine in treatment of chronic heart failure]. Ji-Fang, B; Rui, Q, 2020)	0.56
" This study aimed to assess the effects of NE at different administration time and NE combined with SP treatment on the cardiac function and prognosis of SS."	( Effect of norepinephrine combined with sodium phosphocreatine on cardiac function and prognosis of patients with septic shock. Kang, D; Li, X; Wang, H; Xia, J; Yu, J; Zhao, Y, )	0.13
"BNP combined with echocardiographic parameters has outstanding value to predict the risk of cardioembolic stroke, especially for BNP and LAD."	( BNP combined with echocardiographic parameters to predict the risk of cardioembolic stroke. Ma, A; Pan, X; Peng, Q; Wang, Y; Wei, J; Zhang, M, 2021)	0.62
"To investigate clinical value for the risk model of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in evaluating clinical outcomes and prognosis of patients with acute heart failure (AHF)."	( The role of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in the evaluation of clinical outcomes and prognosis in patients with acute heart failure. Dong, Y; Gao, Q; Jiang, H; Wang, Z; Zhang, Q, 2022)	0.72
"AHFI combined with the EHMRG model was associated with cardiac function status and EHMRG score was positively related to the level of Troponin I, BNP, and NT-proBNP."	( The role of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in the evaluation of clinical outcomes and prognosis in patients with acute heart failure. Dong, Y; Gao, Q; Jiang, H; Wang, Z; Zhang, Q, 2022)	0.72
"AHFI combined with a high EHMRG risk model was associated with clinical outcomes and prognosis."	( The role of acute heart failure index (AHFI) combined with emergency heart failure mortality risk grade (EHMRG) in the evaluation of clinical outcomes and prognosis in patients with acute heart failure. Dong, Y; Gao, Q; Jiang, H; Wang, Z; Zhang, Q, 2022)	0.72
" The aim of this study was to investigate efficacy of levosimendan when combined with rhBNP in patients with diuretic resistance and low ejection fraction (EF) rate."	( Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance. Jun, M; Lan, L; Libiya, Z; Shubin, J; Xiangli, S, 2021)	0.62
"909 when NT-proBNP combined with D-dimer."	( Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention. Diao, Y; Sun, B; Yin, M; Zhang, B, 2021)	0.62
"To investigate the significance of echocardiography combined with N-terminal pro-B-type natriuretic peptide (NT-pro BNP) levels in the evaluation and prognosis of diastolic heart failure (DHF)."	( The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. Chen, S; Li, P; Shi, S; Wu, H; Wu, X; Zhou, Y, 2022)	0.72
"The diagnosis of echocardiography combined with NT-pro BNP levels has the potential to distinguish the NYHA class in heart function of patients with DHF and determine the prognosis of patients."	( The Value of Echocardiography Combined with NT-pro BNP Level in Assessment and Prognosis of Diastolic Heart Failure. Chen, S; Li, P; Shi, S; Wu, H; Wu, X; Zhou, Y, 2022)	0.72
"RDW can predict prognosis in HF at various time-points and combination with NT-proBNP improves the prognostic value."	( Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure. Feng, J; Huang, B; Huang, L; Liang, L; Tian, P; Zhang, J; Zhang, Y; Zhao, L; Zhao, X, 2022)	0.72
"This study was to investigate the correlation between glycated haemoglobin (HbA1c) level, cardiac function, and prognosis in patients with diabetes mellitus combined with myocardial infarction."	( Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction. An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022)	0.72
"HbA1c level in patients with diabetes mellitus combined with myocardial infarction is closely related to the degree of cardiac function damage."	( Correlation between Glycated Haemoglobin Level, Cardiac Function, and Prognosis in Patients with Diabetes Mellitus Combined with Myocardial Infarction. An, H; Fang, D; Li, W; Sun, M; Zeng, G; Zheng, Q, 2022)	0.72
"The value of serum carbohydrate antigen 125 (CA125) combined with N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the evaluation of acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) remains unclear."	( Carbohydrate antigen 125 combined with N-terminal pro-B-type natriuretic peptide in the prediction of acute heart failure following ST-elevation myocardial infarction. Chen, X; Huang, M; Weng, Y; Wu, M; Xu, K; Zhuo, X, 2022)	0.72
"This study examined the effects of recombinant human brain natriuretic peptide (rhBNP) combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure (HF)."	( Effects of recombinant human brain natriuretic peptide combined with tolvaptan on cardiac and renal function and serum inflammatory factors in patients with severe heart failure. Guo, M; Hao, M; Yang, J; Zhang, L, 2023)	0.91

Excerpt	Reference	Relevance
" An imbalance in favour of oxidants leads to oxidative stress, and contributes to myocyte apoptosis, direct negative inotropic effects, and reduced bioavailability of nitric oxide (NO)."	( Role of oxidative and nitrosative stress biomarkers in chronic heart failure. Anzalone, R; Carbone, M; Colombo, M; Di Stefano, A; Eleuteri, E; Giannuzzi, P; Gnemmi, I; La Rocca, G; Magno, F; Tarro Genta, F; Zummo, G, 2009)	0.35
" Further studies exploring whether DPP IV inhibitors increase the bioavailability of BNP(1-32), delay the progression of heart failure, and increase the efficacy of exogenous administration of BNP(1-32) in decompensated heart failure are needed."	( Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Bartunek, J; De Meester, I; Goethals, M; Lambeir, AM; Scharpé, S; Vanderheyden, M; Verstreken, S, 2009)	0.35
"The lungs of patients with pulmonary arterial hypertension (PAH) exhibit decreased bioavailability of nitric oxide and downstream signaling through cyclic guanosine monophosphate (cGMP)."	( Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension. Alpert, MA; Carlino, C; Dellsperger, KC; Demarco, VG; Grueber, RE; Heller, RL; Schneider, RI; Tobias, JD, 2010)	0.36
" Further studies are needed to explore whether DPP IV inhibitors increase the bioavailability of BNP(1-32), delay the progression of heart failure and increase the efficacy of exogenously administered BNP(1-32) in decompensated heart failure."	( B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications. Bartunek, J; Beunk, J; Goethals, M; Vanderheyden, M; Verstreken, S; Vrints, C, 2010)	0.36
" A phase I clinical trial of a novel H2 S prodrug (SG1002) was designed to assess safety and changes in H2 S and NO bioavailability in healthy and HF subjects."	( A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients. Giordano, T; Gojon, G; Krum, H; Li, Z; Pattillo, CB; Polhemus, DJ, 2015)	0.42
" ProANP is found in the human circulation, but its bioavailability is undefined."	( Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. Burnett, JC; Huntley, BK; Ichiki, T; Sangaralingham, SJ, 2015)	0.42
"Prior studies have suggested that transfusion of stored red blood cells (RBCs) with increased levels of cell-free hemoglobin might reduce the bioavailability of recipient nitric oxide (NO) and cause myocardial strain."	( B-type natriuretic peptide and plasma hemoglobin levels following transfusion of shorter-storage versus longer-storage red blood cells: Results from the TOTAL randomized trial. Ainomugisha, B; Cserti-Gazdewich, C; Ddungu, H; Dhabangi, A; Dzik, WH; Kyeyune, D; Musisi, E; Opoka, R; Stowell, CP, 2017)	0.46
"The heart plays a pivotal role as a regulator of the endocrine response in systolic dysfunction, not only by directly releasing NPs but also by contributing to circulating sNEP, which in turn determines the bioavailability of other numerous vasoactive peptides."	( The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin. Arrigo, M; Ballan, P; Bizouarn, P; Carpentier, A; Cholley, B; Cohen-Solal, A; Gendron, N; Latremouille, C; Launay, JM; Ludes, PO; Mebazaa, A; Nougué, H; Pemberton, CJ; Pottecher, J; Richards, AM; Sadoune, M; Samuel, JL; Singh, JP; Smadja, DM; Szymonifka, J; Truong, QA; Vodovar, N, 2018)	0.48
"Vericiguat pharmacokinetics were well described by a one-compartment model with apparent clearance, apparent volume of distribution, and absorption rate constant."	( Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Austin, R; Becker, C; Frei, M; Garmann, D; Grevel, J; Klein, D; Meyer, M; Pieske, B; Roessig, L; Ruehs, H, 2021)	0.62
" Altogether, our results identified BNP and all therapies aimed to increase BNP's bioavailability as new cardioprotective targets as BNP treatment leads to an increased number of CMs in neonatal, adult unmanipulated and infarcted hearts."	( Brain Natriuretic Peptide Protects Cardiomyocytes from Apoptosis and Stimulates Their Cell Cycle Re-Entry in Mouse Infarcted Hearts. Bielmann, C; Bon-Mathier, AC; Déglise, T; Mazzolai, L; Rignault-Clerc, S; Rosenblatt-Velin, N, 2022)	0.72

Excerpt	Relevance	Reference
" In the presence of dithiothreitol, the dose-response curve of guanylate cyclase activation was shifted rightward by a factor of 30."	( Characterization and regulation of atrial natriuretic peptide (ANP)-R1 receptors in the human neuroblastoma cell line NB-OK-1. Christophe, J; Delporte, C; Gossen, D; Poloczek, P; Tastenoy, M; Winand, J, 1991)	0.28
" Further elucidation of the possible role of BNP as a circulating hormone in man awaits measurement of tissue and plasma concentrations of human BNP in health and disease and provision of fuller dose-response data for human as well as porcine BNP."	( Brain natriuretic peptide administered to man: actions and metabolism. Espiner, E; Ikram, H; McGregor, A; Richards, M; Yandle, T, 1990)	0.28
" This inhibition reflects the ability of GnRH to shift the CNP dose-response curve rightward (increasing the EC50 for CNP action approximately 10-fold both with and without 3-isobutyl-1-methylxanthine)."	( Cyclic guanosine monophosphate production in the pituitary: stimulation by C-type natriuretic peptide and inhibition by gonadotropin-releasing hormone in alpha T3-1 cells. Käppler, K; McArdle, CA; Poch, A, 1993)	0.29
" The present study was designed to examine the relationship between the dosing (intravenous constant infusion) rates and the diuretic actions of alpha-rat atrial natriuretic peptide (alpha-rANP) and rat brain natriuretic peptide (rBNP) in rats, and population (nonlinear mixed effect model) analysis was applied to these complicated diuretic actions."	( Nonlinear mixed effect modeling of the pharmacodynamics of natriuretic peptides in rats. Hama, N; Hashimoto, Y; Hori, R; Imura, H; Mori, S; Nakao, K; Yamaguchi, M; Yasuhara, M, 1993)	0.29
" In the present work we determine ANF and BNP synthesis and secretion in the aortic-banded rat treated with dosage schedules of the ACE inhibitor ramipril that result in the prevention or regression of both hypertension and hypertrophy (high dosage) or in the prevention or regression of hypertrophy alone with persistent hypertension (low dosage)."	( Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Bruneau, BG; Chen, JH; de Bold, AJ; Eid, H; Kuroski de Bold, ML; Linz, W; Ogawa, T; Schölkens, BA; Stevenson, M, 1996)	0.29
" The dose-response curve was bell-shaped."	( Pituitary adenylate cyclase-activating polypeptide protects rat-cultured cortical neurons from glutamate-induced cytotoxicity. Hirai, A; Morio, H; Saito, Y; Tamura, Y; Tatsuno, I, 1996)	0.29
"We investigated 45 patients (age 55 +/- 10 years) with stable CHF who presented with a maintenance dosage of enalapril of either 5 mg given twice daily (E10; n = 16), 10 mg given twice daily (E20; n = 18), or 20 mg given twice daily (E40; n = 11)."	( Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Brunner-La Rocca, HP; Candinas, R; Follath, F; Kiowski, W; Maly, FE; Weilenmann, D, 1999)	0.3
" Thus patients with congestive heart failure may benefit from increasing dosage of ACE inhibitors."	( Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Brunner-La Rocca, HP; Candinas, R; Follath, F; Kiowski, W; Maly, FE; Weilenmann, D, 1999)	0.3
"Twenty patients with mild to moderate CHF receiving stable conventional therapy including an ACE inhibitor were randomly assigned to titration of ACE inhibitor dosage according to serial measurement of plasma BNP concentration (BNP group) or optimal empirical ACE inhibitor therapy (clinical group) for 8 weeks."	( Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Blue, L; Byrne, J; Dargie, HJ; Farmer, R; McDonagh, TA; Morton, JJ; Murdoch, DR, 1999)	0.3
" In the second study two BNP (n = 5) or ANP (n = 5) dose-response curves were performed in order to assess the repeatability of the BNP/ANP infusions."	( Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. de Leeuw, PW; Houben, AJ; Kroon, AA; van der Zander, K, 1999)	0.3
" The slopes of the BNP dose-response curves differed significantly from those of the ANP curves (18."	( Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. de Leeuw, PW; Houben, AJ; Kroon, AA; van der Zander, K, 1999)	0.3
"5% 2 h after dosing with 8 mg of candesartan cilexetil."	( Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. Yasue, H; Yoshimura, M, 2000)	0.31
" Plasma atrial and brain natriuretic peptide and cGMP levels were stable acutely (P=NS), while brain natriuretic peptide increased after repeated dosing in severe HF (P<0."	( Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Espiner, EA; Frampton, CM; Nicholls, MG; Powell, JD; Rademaker, MT; Richards, AM; Troughton, RW; Yandle, TG, 2000)	0.31
" Patients who could not be dosed with up to 40 mg daily of metoprolol or 20 mg daily of carvedilol were defined as intolerant."	( Comparative left ventricular functional and neurohumoral effects of chronic treatment with carvedilol versus metoprolol in patients with dilated cardiomyopathy. Hanatani, A; Hirooka, K; Hori, M; Ishida, Y; Komamura, K; Miyatake, K; Nakatani, S; Yamagishi, M; Yasumura, Y, 2001)	0.31
" The purpose was to measure the effect of ibuprofen on urinary excretion of aquaporin-2 (u-AQP2), urinary output, urinary osmolality (u-osm) and plasma concentration of vasopressin (AVP) in a dose-response study using placebo and ibuprofen 600mg and 1200mg."	( Effect of an acute oral ibuprofen intake on urinary aquaporin-2 excretion in healthy humans. Bech, JN; Bentzen, H; Pedersen, EB; Pedersen, RS, 2001)	0.31
" Optimal dosing will become increasingly difficult to judge."	( BNP in hormone-guided treatment of heart failure. Lainchbury, JG; Nicholls, MG; Richards, AM; Troughton, RW; Yandle, TG, )	0.13
" At first, BNP dosage is a potential tool for detecting heart failure and left ventricular dysfunction."	( [Ultra-rapid measurement of brain natriuretic peptide]. Logeart, D, 2002)	0.31
" However, the dosage of the ACE inhibitor influenced short-term survival in this population."	( Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Berger, R; Bergler-Klein, J; Bojic, A; Hülsmann, M; Pacher, R; Sturm, B; Woloszczuk, W, 2002)	0.31
" Little is known about its safety, efficacy, pharmacokinetics, and dosing profile in children."	( The Pediatric Randomized Carvedilol Trial in Children with Heart Failure: rationale and design. Boucek, MM; Burch, GH; Burr, J; Curtin, EL; Hsu, DT; LaSalle, B; Mahony, L; Pahl, E; Schlencker-Herceg, R; Shaddy, RE; Sower, B; Tani, LY, 2002)	0.31
"In our population BNP dosage confirms the high negative predictive value reported in the literature and may be useful to exclude diagnosis of CHF in patients with suspect signs and symptoms."	( [Diagnosis of heart failure in general medicine: role of cerebral natriuretic peptide. Results of a pilot study of a population sample from Calabria]. Battista, F; Caporale, R; Misuraca, G; Plastina, F; Serafini, O, 2002)	0.31
" Bed-side dosage of B-type natriuretic peptide is useful to make or exclude the diagnosis of heart failure in patients with acute dyspnea from various causes."	( [Diagnosis of systolic heart failure]. André-Fouët, X; Ginon, I; Thivolet, S, 2002)	0.31
" When remarkable hemodynamic changes appeared rhBNP was infused intravenously at the dosage of 10, 30 and 100 ng."	( [Recombinant human brain natriuretic peptide on the cardiac hemodynamics and renal function in dogs with heart failure]. Liu, HX; Xu, XW; Yang, Y; Zeng, GY, 2002)	0.31
"048 g/cm(2)), indicating a dosage effect."	( Association of the -381T/C promoter variation of the brain natriuretic peptide gene with low bone-mineral density and rapid postmenopausal bone loss. Emi, M; Ezura, Y; Hosoi, T; Inoue, S; Ishida, R; Iwasaki, H; Kajita, M; Kodaira, M; Orimo, H; Shiraki, M; Suzuki, T; Yoshida, H, 2003)	0.32
" It is a sensitive marker of ventricular dysfunction in symptomatic and asymptomatic patients, and its dosage is correlated with the severity of the dysfunction."	( [B-type natriuretic peptide for the diagnostic and prognostic assessment in cardiology. Its interest and perspectives of application]. Bergmann, JF; Devaux, JY; Fulla, Y; Martins, E; Meune, C, 2003)	0.32
"We tested the hypothesis that, in heart transplant recipients, plasma aminoterminal pro-brain natriuretic peptide (NT-proBNP) dosage is useful for diagnosis of high ventricular loading pressures in the absence of systolic dysfunction."	( Aminoterminal pro-brain natriuretic peptide and ventricular filling pressures in heart transplant recipients. Ambrosi, P; Aviérinos, JF; Bouvenot, G; Habib, G; Métras, D; Oddoze, C; Portugal, H; Riberi, A; Vailloud, JM, 2003)	0.32
" All underwent clinical and echocardiographic evaluations and a test to determine the serum dosage of ProBNP."	( ProBNP for stratifying patients with heart failure. Cassaro-Strunz, C; de Oliveira, MT; Franco, FG; Pereira-Barretto, AC, 2003)	0.32
" A ProBNP dosage test was an excellent auxiliary in the clinical characterization of patients with HF."	( ProBNP for stratifying patients with heart failure. Cassaro-Strunz, C; de Oliveira, MT; Franco, FG; Pereira-Barretto, AC, 2003)	0.32
" The decrease in BNP was significantly associated with ACE-i dosage and with the use of a beta-blocker."	( Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Azevedo, A; Bettencourt, P; Dias, P; Ferreira, A; Friões, F; Pimenta, J; Rocha-Gonçalves, F, 2004)	0.32
" The decrease in BNP levels was proportional to ACE-i dosage and larger among patients on beta-blockers."	( Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Azevedo, A; Bettencourt, P; Dias, P; Ferreira, A; Friões, F; Pimenta, J; Rocha-Gonçalves, F, 2004)	0.32
" Patients were randomized to different dosage levels of darusentan (30, 100, or 300 mg) for 3 weeks."	( Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. Berger, R; Bergler-Klein, J; Bojic, A; Pacher, R; Stanek, B, 2004)	0.32
"Utility of the dosage of brain natriuretic factor (BNP) in the diagnosis and treatment of heart failure."	( [Use of brain natriuretic peptide (BNP) in the diagnosis and treatment of heart failure]. Martin-Du Pan, RC; Ricou, F, 2003)	0.32
" When the diuretic dosage was increased on clinical grounds, SP-B had increased 39% (P<0."	( Plasma surfactant protein-B: a novel biomarker in chronic heart failure. Arnolda, LF; Aylward, PE; Bersten, AD; Chew, DP; De Pasquale, CG; Doyle, IR, 2004)	0.32
" The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed."	( Nesiritide during extracorporeal membrane oxygenation. Berkenbosch, JW; Gustafson, RA; Rosen, DA; Rosen, KR; Russo, P; Siu, BL; Smith, T; Tobias, JD, 2005)	0.33
" The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy."	( Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin Hayama, M; Higashihara, M; Kajiwara, K; Khori, M; Niitsu, N; Tamaru, J, 2005)	0.33
" Dose-response curves revealed that at 100 microM, the vessel dilator decreased 92% of the cancer cells in 24 h while BNP had no effect, but CNP caused a 39% decrease."	( Five cardiac hormones decrease the number of human small-cell lung cancer cells. Alli, AA; Fitz, SR; Gower, WR; Sanchez-Ramos, J; Solivan, SM; Song, S; Vesely, BA; Vesely, DL, 2005)	0.33
" No consistent relationship existed between the expression of putative transcriptional targets and Nkx2-5 gene dosage in the physiologically relevant range."	( Haploinsufficiency of the cardiac transcription factor Nkx2-5 variably affects the expression of putative target genes. Dorfman, AL; Izumo, S; Jay, PY; Lu, Y; Rozhitskaya, O; Sherwood, MC; Tarnavski, O; Ueyama, T, 2005)	0.33
" The dosage of beta-blockers were increased gradually to target or the tolerant dosages (bisoprolol 10 mg qd, carvedilol 25 mg bid) during 3 months in 36 patients."	( [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure]. Bian, WY; Duan, B; Jia, X; Li, W; Li, YS; Wang, F; Wang, L; Xu, ZM, 2005)	0.33
"Bedside dosage of B-type natriuretic peptide as a marker of congestive heart failure is of major interest in the evaluation of acute dyspnea."	( [Acute dyspnea: what is the diagnostic role of B-type natriuretic peptide?]. Sarasin, FP, 2005)	0.33
"Nesiritide, in combination with standard therapy, significantly lowered the endogenous concentrations of natriuretic peptides during infusion and after dosing was completed."	( Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Bhalla, V; Chiu, A; Clopton, P; Cremo, R; Fitzgerald, RL; Gardetto, N; Maisel, AS, 2005)	0.33
" The clinical group had beta-blocker dosage increased according to standard care, whereas the BNP group had beta-blocker dosage up-titrated according to plasma BNP levels plus standard care."	( BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. Beck-da-Silva, L; de Bold, A; Fraser, M; Haddad, H; Williams, K, )	0.13
"Sixty-six patients with chronic heart failure were randomly divided into 2 groups: low-dose group, treated by perindopril with the dosage of 2 mg/d initially and gradually increased up to 2-4 mg/d, and high-dose group, treated by perindopril with the dosage of 2 mg/d initially and gradually increased up to 8 approximately 10 mg/d."	( [Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure]. Deng, B; Luo, M; Song, HM; Zhang, J, 2005)	0.33
" This case report demonstrates the lack of adverse events in a pediatric patient administered nesiritide beyond the recommended dosing parameters."	( Administration of a large nesiritide bolus dose in a pediatric patient: case report and review of nesiritide use in pediatrics. Clunie, S; Denfield, S; Dreyer, WJ; Jefferies, JL; Moffett, BS; Price, JF; Towbin, JA, 2006)	0.33
"The dosage of plasma levels of NT-proBNP is useful into patients with suspected HFS, if the other methods of diagnosis are not reliable."	( [The correlation between NT-proBNP plasma levels and heart failure syndrome]. Chendereş, RM; Enea, E; Glişici, M; Nanu, PD; Puşchiţă, M, )	0.13
" As far as the prescription of diuretics go, drugs which are effective in a condition associated with a poor quality of life, it is important to use the minimal dosage because of their deleterious stimulant effects on the rennin-angiotensin-aldosterone system and their metabolic side effects."	( [The diuretic in chronic cardiac failure: a clumsy partner]. Rocca, C, 2006)	0.33
" Data about BNP dosage for cardiovascular monitoring of patients with ALA on renal replacement therapy are lacking."	( Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis. Cantelli, S; Catizone, L; Fabbian, F; Molino, C; Russo, G; Russo, M; Sartori, S; Stabellini, N, 2006)	0.33
" BNP levels did not correlate with erythrocyte sedimentation rate/C-reactive protein levels, SLEDAI scores, total steroid dosage used, or other echocardigraphic parameters."	( B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Akdogan, A; Aksoyek, S; Atalar, E; Calguneri, M; Ertenli, AI; Kalyoncu, U; Karadag, O; Kiraz, S; Ozmen, F; Yavuz, B, 2007)	0.34
"FUSION II is a 900-patient randomized, placebo-controlled, double-blind, phase IIb trial designed to further assess the safety, efficacy, and optimal dosing frequency of outpatient nesiritide for advanced heart failure."	( The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: study rationale and design. Cheng, M; Evans, R; Kim, SS; Krum, H; Massie, BM; Silver, MA; Stevenson, LW; Yancy, CW, 2007)	0.34
"We demonstrated that as the drug dosage increased, systolic ejection fraction (EF) and shortening fraction (FS) values decreased (EF r2=0."	( Early prediction of anthracycline induced cardiotoxicity. Can, M; Demirtas, S; Erkus, B; Genc, Y; Karaca, L; Yarpuzlu, AA, 2007)	0.34
"05), whereas the mean increase in furosemide dosage was similar in both groups."	( Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. Aumont, MC; Aupetit, JF; Cohen-Solal, A; Donal, E; Eicher, JC; Funck, F; Galinier, M; Gueffet, P; Jondeau, G; Jourdain, P; Juillière, Y; Le Helloco, A, 2007)	0.34
" Few studies have demonstrated that hormone dosage can add clinical and prognostic information with respect to the traditional laboratory analysis (i."	( Emerging cardiac markers in coronary disease: role of brain natriuretic peptide and other biomarkers. Gallotta, M; Iovine, F; Nuti, R; Palazzuoli, A, 2007)	0.34
" When used for approved indications and according to recommended dosage and administration regimens, nesiritide represents a reasonable treatment adjunct for ADHF."	( Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure. Yancy, CW, 2007)	0.34
"Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0."	( Carvedilol for children and adolescents with heart failure: a randomized controlled trial. Blume, ED; Boucek, MM; Boucek, RJ; Burr, J; Canter, CE; Dodd, DA; Holubkov, R; Hsu, DT; LaSalle, B; Lukas, MA; Mahony, L; Pahl, E; Rosenthal, DN; Ross, RD; Shaddy, RE; Tani, LY, 2007)	0.34
" Doppler-echocardiography and the dosage of BNP can probably help to detect and consequently to treat prematurely heart failure in the diabetic patient."	( [Diabetes and heart failure, a fatal association]. Cohen-Solal, A; Logeart, D, )	0.13
" Few studies demonstrated that hormones dosage could add clinical and prognostic information respect to the traditional laboratory analysis (i."	( Natriuretic peptides in coronary disease with non-ST elevation: new tools ready for clinical application? Giannotti, G; Iovine, F; Nuti, R; Palazzuoli, A, 2007)	0.34
" The mean dosing interval was 66."	( Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience. Best, M; Dembo, L; Driscoll, GO; Parle, NM; Thomas, MD, 2008)	0.35
"05) and this effect showed a dose-response relationship."	( B-type natriuretic peptide decreases gastric emptying and absorption. Addisu, A; Dietz, JR; Gower, WR; Landon, CS, 2008)	0.35
" Patients without noticeable changes in left ventricular ejection fraction with a low to moderate carvedilol dosage show an increase in NT Pro BNP plasma levels."	( N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol. Cokkinos, DV; Dritsas, A; Kallistratos, MS; Laoutaris, ID, )	0.13
" B-type natriuretic peptide dosage is also able to uncover new onset of left heart failure associated with weaning difficulties from mechanical ventilation in chronic obstructive pulmonary disease patients."	( Detection of acute heart failure in chronic obstructive pulmonary disease patients: role of B-type natriuretic peptide. Abroug, F; Ouanes-Besbes, L, 2008)	0.35
" In all patients, diuretics were administered according to a standardized dosing algorithm."	( The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. Burnett, JC; Chen, HH; Frantz, RP; Hodge, DO; Karon, BL; Miller, WL; Owan, TE; Redfield, MM; Rodeheffer, RJ, 2008)	0.35
" The clinical experience including indications for use, contraindications, dosage and monitoring has been reviewed."	( Nesiritide: the clinical experience. Weeks, SG, 2008)	0.35
" In all patients we performed echocardiographic examination, dosage of plasma brain natriuretic peptide, serum carboxy-terminal propeptide and telopeptide of procollagen type I and amino-terminal propeptide of procollagen type III at days 1 and 3, and at 1 and 6 months after index infarction."	( Time course of serum collagen types I and III metabolism products after reperfused acute myocardial infarction in patients with and without systemic hypertension. Antoniucci, D; Buonamici, P; Cerisano, G; Dovellini, EV; Migliorini, A; Parodi, G; Raspanti, S; Taddeucci, E; Tommasi, M; Valenti, R, 2009)	0.35
" Despite increasing numbers of studies using NPs in therapy of acute and chronic CHF, several controversies regarding safety, efficacy, and dosing of NPs need to be addressed."	( Insights into natriuretic peptides in heart failure: an update. Boerrigter, G; Burnett, JC; Korinek, J; Mohammed, SF, 2008)	0.35
"14); furosemide dosage (0."	( Nesiritide following maze and mitral valve surgery. Arnaoutakis, GJ; Beaver, TM; Ejaz, AA; Hess, PJ; Martin, TD; Peng, YG; Winterstein, A, )	0.13
" Indomethacin dosing was withheld in the BNP-guided group if the 12 or 24 h BNP concentrations were found to be <100 pg/ml."	( B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Attridge, JT; Kaufman, DA; Lim, DS, 2009)	0.35
"To evaluate the usefulness of monthly brain natriuretic peptide (BNP) dosage in assessing dry weight in hemodialysis patients."	( Brain natriuretic peptide variations are linked to volume status in hemodialysis patients. Abbassi, A; Chauffert, ML; Kihal, K; Martin, E; Poli, I; Roueff, S; Saint-Georges, M; Yazbeck, F, 2008)	0.35
"Thirty-three newly diagnosed breast cancer patients who received a total doxorubicin dosage of 240 mg/m2 over four treatment cycles as part of adjuvant chemotherapy after curative breast surgery were included in this study."	( Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Akin, AM; Alan, S; Altintas, A; Cil, T; Isikdogan, A; Kaplan, AM, 2009)	0.35
"Several studies have demonstrated the usefulness of B-type natriuretic peptide (BNP) dosage in patients referring for acute dyspnea in the emergency department."	( [B-type natriuretic peptide and Doppler echocardiography in the diagnosis of heart failure: alternative or complementary tools?]. Agricola, E; Ballo, P; Buralli, S; D'Andrea, A; D'Errico, A; Galderisi, M; Gallotta, M; Losi, MA; Mele, D; Mondillo, S; Nistri, S; Nuti, R; Palazzuoli, A; Sciomer, S, 2009)	0.35
" Thus, it may prove more efficient to develop efforts to increase physicians' adhesion to guidelines than to rely on the dosage of a biomarker."	( [BNP-guided therapy of chronic heart failure: what is the evidence?]. Copt, C; Nendaz, M, 2009)	0.35
"Our data showed that BNP could not be dosed on different collection tubes without altering the results."	( Measurement of Type B natriuretic peptide in heparin and K(2) EDTA plasma. Cemin, R; Daves, M; Pusceddu, I, 2010)	0.36
" There was a reduction in the dosage and in the number of patients who were treated with paricalcitol and sevelamer."	( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010)	0.36
" It allows reduction of vitamin D deficiency, better control of mineral metabolism with less use of active vitamin D, attenuation of inflammation, reduced dosing of erythropoiesis-stimulating agents, and possibly improvement of cardiac dysfunction."	( Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Aires, I; Amaral, T; Borges, M; Cortez, J; Ferreira, A; Ferreira, C; Gil, C; Jorge, C; Matias, PJ, 2010)	0.36
" Verapamil heart tissue and plasma levels after intraperitoneal dosing of spontaneously hypertensive and normotensive rats were investigated."	( Impaired tissue clearance of verapamil in rat cardiac hypertrophy results in transcriptional repression of ion channels. Borlak, J; Zwadlo, C, 2010)	0.36
"The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	0.36
" Similar proportions of patients tolerated qd vs bid dosing (bid 67% vs qd 68%)."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	0.36
"Valsartan administered qd has a similar safety and tolerability profile with comparable 24-hour RAAS blockade, as assessed by increases in PRA, as bid dosing in patients with moderate to severe (NYHA class II-III) heart failure."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	0.36
" dosage effect), with an increase associated with two copies that varied between 20 and 100 pg/ml across populations."	( Genome-wide association analysis and fine mapping of NT-proBNP level provide novel insight into the role of the MTHFR-CLCN6-NPPA-NPPB gene cluster. Del Greco M, F; Franke, A; Fuchsberger, C; Heid, IM; Hicks, AA; Krawczak, M; Luchner, A; Melville, SA; Minelli, C; Pattaro, C; Peters, A; Pichler, I; Pramstaller, PP; Schreiber, S; Wichmann, HE; Wiedermann, CJ; Winkler, T, 2011)	0.37
" However, no study has evaluated the comparative safety, efficacy, and biomarkers of optimally dosed nesiritide versus nitroglycerin in ADHF."	( Renal function and neurohormonal changes following intravenous infusions of nitroglycerin versus nesiritide in patients with acute decompensated heart failure. Chew, E; Chow, SL; Heywood, JT; O'Barr, SA; Pak, F; Patel, P; Patterson, JH; Peng, J; Quist, R, 2011)	0.37
"01) while dosage of beta-blocker therapy has been comparable in both groups."	( [Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry]. Altenberger, J; Dornaus, C; Ebner, C; Fruhwald, FM; Kaltenbach, L; Pacher, R; Pölzl, G; Reiter, S; Ulmer, H; Wieser, M, 2011)	0.37
"To explore the safety of intravenous recombinant human brain natriuretic peptide (rhBNP) in treating acute decompensated heart failure and acute exacerbation of chronic heart failure, and to compare the differences in efficacy with different dosage and administration time."	( [Efficacy and safety of intravenous recombinant human brain natriuretic peptide in patients with decompensated acute heart failure: a multicenter, randomized, open label, controlled study]. Hu, DY, 2011)	0.37
"Retrospective medical records analysis of all patients hospitalised between January 2003 and May 2009 with the final diagnosis of acute exacerbation of COPD, and who had undergone BNP dosage at admission followed by an echocardiography."	( Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Agoritsas, T; Delabays, A; Gariani, K; Perneger, TV, 2011)	0.37
"To explore efficacy and safety of a modified dosage regimen of nesiritide in patients (≥75 years) with acute heart failure (AHF)."	( Efficacy and safety of a modified dosage regimen of nesiritide in patients older than 75 years with acute heart failure. Bai, Y; Fu, S; Luo, L; Wang, H; Wang, L; Ye, P; Yi, S; Zhu, B, 2012)	0.38
"In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment."	( Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2012)	0.38
" Anemia is a deteriorating situation that causes increase of drug dosing in patients with heart failure."	( Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia. Büyüklü, M; Kürüm, AT; Set, T; Tatlý, E, 2012)	0.38
" The cumulative doxorubicin dosage was 240 mg/m(2) according to the AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) ALL 2000 protocol."	( Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. De Nisco, A; De Rosa, G; Leo, A; Maurizi, P; Mordente, A; Riccardi, R; Rizzo, D; Ruggiero, A; Vendittelli, F; Zuppi, C, 2013)	0.39
" CRP quartiles 1 and 2 showed no significant difference followed by a significant inverse dose-response relationship."	( Association of objectively measured physical activity with established and novel cardiovascular biomarkers in elderly subjects: every step counts. Denkinger, M; Klenk, J; Koenig, W; Nikolaus, T; Peter, R; Rothenbacher, D, 2013)	0.39
"There is a dose-response relationship in women between the severity of sleep apnea during the night and the levels of BNP in the morning."	( Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women. Lindahl, B; Lindberg, E; Ljunggren, M; Theorell-Haglöw, J, 2012)	0.38
"Results from the DOSE-AHF study suggest that an initial continuous infusion of loop diuretics is not superior to bolus dosing with regard to clinical endpoints in acute heart failure."	( Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Braunwald, E; Felker, GM; Givertz, MM; McNulty, S; O'Connor, CM; Shah, RV, 2012)	0.38
"The dosage of natriuretic peptides improves diagnostic performance in patients with acute dyspnea when combined with clinical elements."	( [Performance of natriuretic peptide as a marker in patients with chronic obstructive pulmonary disease]. Gariani, K; Marti, C; Perrier, A, 2012)	0.38
" Carvedilol maintenance dosage was lower in patients with preserved EF (7."	( Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Hiramatsu, K; Kobayashi, F; Mori, Y; Nishikawa, Y, 2013)	0.39
" New insight has been gained regarding volume management, including dosing strategies for intravenous loop diuretics and the role of ultrafiltration in patients with heart failure and renal dysfunction."	( Acute decompensated heart failure: update on new and emerging evidence and directions for future research. Albert, NM; Butler, J; Carson, PE; Collins, SP; Colvin-Adams, M; Dimarco, JP; Ezekowitz, JA; Fang, JC; Givertz, MM; Hernandez, AF; Hershberger, RE; Katz, SD; Krishnamani, R; Rogers, JG; Spertus, JA; Starling, RC; Stevenson, WG; Stough, WG; Sweitzer, NK; Tang, WH; Teerlink, JR; Walsh, MN; Westlake Canary, CA, 2013)	0.39
" BNP and NT-proBNP were dosed with commercial kits."	( Depletion of proBNP1-108 in patients with heart failure prevents cross-reactivity with natriuretic peptides. Cristol, JP; Davy, JM; Delseny, D; Dupuy, AM; Fareh, J; Guerrier, L; Larue, C; Leclercq, F; Merle, D; Pasquie, JL; Roubille, F; Salvetat, N, 2013)	0.39
" All patients underwent echocardiography in their acute phase and benefited from the dosage of BNP during the first 4 hours."	( [Is BNP assay useful for the diagnosis of acute dyspnea in emergencies departments?]. Ben Ammar, L; Borsali Falfoul, N; Drissa, H; Hamouda, C; Kaabachi, N; Lakhdhar, R; Majed, K; Moncef, F, )	0.13
"Time spent walking was associated with reduced risk of onset of stroke in dose-response fashion, independent of walking pace."	( Protective effect of time spent walking on risk of stroke in older men. Jefferis, BJ; Papacosta, O; Wannamethee, SG; Whincup, PH, 2014)	0.4
" Therefore, we decided to execute a meta-analysis of published randomized controlled trials (RCTs) to test the hypothesis that an improvement of clinical outcomes in outpatients with CHF may be achieved by adjustment of pharmacologic dosing performed according to natriuretic peptide determinations."	( B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis. Ariano, C; Cioppa, C; De Vecchis, R; Di Biase, G; Esposito, C; Giasi, A, 2014)	0.4
" Use of additional antihypertensive medication, ultrafiltration volume, and dialysis dosage were not different."	( No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Bibby, BM; Christensen, KL; Jensen, JD; Jensen, LT; Jespersen, B; Kjaergaard, KD; Novosel, MK; Peters, CD; Sloth, E; Strandhave, C; Tietze, IN, 2014)	0.4
" Concerning the treatment, recent data suggest that fluid removal, which is often indicated in such instances, could be guided by the dosage of B-type natriuretic peptide."	( Weaning the cardiac patient from mechanical ventilation. Dres, M; Monnet, X; Teboul, JL, 2014)	0.4
" Results showed that the fusion protein HSA-(BNP)2 activated human natriuretic peptide receptor A (hNPR-A) with potency similar to that of BNP, despite using a 10-fold higher dosage than BNP."	( The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins. Deng, L; Ding, Y; Fu, Q; Jin, J; Peng, Y; Wu, Y, 2014)	0.4
" The central venous pressure ( CVP ), mean arterial pressure ( MAP ) and the time reaching their standard values, and the norepinephrine dosage and 3-day fluid balance in severe septic shock patients were compared between milrinone and non-milrinone usage groups."	( [Value of pulse indicator continuous cardiac output monitoring of cardiac function in septic shock patients: a prospective study]. Guo, X; Yao, G; Yi, M, 2015)	0.42
" The heart rate (HR), mean arterial pressure (MAP), central venous pressure (CVP), and dosage of vasoactive drugs before and 1 day and 5 days after treatment were determined for hemodynamics assessment."	( [Effect of Xuebijing injection on hemodynamics and endothelial function in patients with severe sepsis: a prospective study]. Guo, L; He, J; Tan, Z; Zhang, M, 2015)	0.42
"After treatment, HR, MAP, CVP, Lac, ScvO2, and Pv-aCO2 were improved in both groups compared with those before treatment, and the dosage of norepinephrine (NE) was decreased in Xuebijing group."	( [Effect of Xuebijing injection on hemodynamics and endothelial function in patients with severe sepsis: a prospective study]. Guo, L; He, J; Tan, Z; Zhang, M, 2015)	0.42
"After treatment, HR, MAP, CVP, Lac, ScvO2, and Pv-aCO2 were improved in both groups compared with those before treatment, and the dosage of norepinephrine (NE) was decreased in Xuebijing group."	( [Effect of Xuebijing injection on hemodynamics and endothelial function in patients with severe sepsis: a prospective study]. Guo, L; He, J; Tan, Z; Zhang, M, 2015)	0.42
" Cross-sectional study that evaluated 48 patients between 6 and 18 years-old that underwent a six-minute walk test (6MWT), respiratory muscle strength, dosage of B-type natriuretic peptide and echocardiography."	( Exercise capacity in children and adolescents with corrected congenital heart disease. Coronel, CC; Feltez, G; Lukrafka, JL; Pellanda, LC, 2015)	0.42
" Ultimately, crizotinib was administrated at a dose of 250 mg twice daily every 3 day dosing for 13 months with maintenance of the anti-tumor effect."	( Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report. Chubachi, K; Fukuizumi, A; Gemma, A; Kato, Y; Kubota, K; Kunugi, S; Matsumoto, M; Minegishi, Y; Miyanaga, A; Nakamichi, S; Noro, R; Seike, M, 2015)	0.42
" The influence of the different diagnostic tests on diuretic dosing was assessed descriptively and in linear regression analyses."	( Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study. Dalen, H; Graven, T; Gundersen, GH; Haug, HH; Kleinau, JO; Norekval, TM; Skjetne, K, 2016)	0.43
" Dosing of diuretics differed between the teams in 31 out of 119 consultations."	( Adding point of care ultrasound to assess volume status in heart failure patients in a nurse-led outpatient clinic. A randomised study. Dalen, H; Graven, T; Gundersen, GH; Haug, HH; Kleinau, JO; Norekval, TM; Skjetne, K, 2016)	0.43
" The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point."	( Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Kraigher-Krainer, E; Lam, CS; Maggioni, AP; Müller, K; Pieske, B; Ponikowski, P; Roessig, L; Samano, ET; Shah, SJ; Solomon, SD, 2015)	0.42
" The exploratory secondary analysis suggested a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level (P < ."	( Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Kraigher-Krainer, E; Lam, CS; Maggioni, AP; Müller, K; Pieske, B; Ponikowski, P; Roessig, L; Samano, ET; Shah, SJ; Solomon, SD, 2015)	0.42
" Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF."	( Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. Butler, J; Filippatos, G; Gheorghiade, M; Greene, SJ; Kraigher-Krainer, E; Lam, CS; Maggioni, AP; Müller, K; Pieske, B; Ponikowski, P; Roessig, L; Samano, ET; Shah, SJ; Solomon, SD, 2015)	0.42
"Prospective monocenter observational study including all consecutive patients who received LT for cirrhosis and for whom a preoperative BNP serum dosage was available between January 2011 and December 2014."	( Prognostic Value of Preoperative Brain Natriuretic Peptide Serum Levels in Liver Transplantation. Cohen, J; Delefosse, D; Gayat, E; Guillemet, L; Janny, S; Khoy-Ear, L; Paugam-Burtz, C; Toussaint, A; Weiss, E, 2016)	0.43
"The objective of this study was to establish the benefit of bisoprolol up-titration toward recommended dosage targets, versus lower-dose maintenance, in heart failure (HF) patients with systolic dysfunction."	( Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction. Cha, TJ; Choi, DJ; Choi, SW; Han, SW; Hwang, KK; Jeon, H; Kim, HJ; Kim, JH; Kim, SH; Kim, YJ; Ryu, KH; Shim, WJ; Shin, MS; Yoo, BS, 2016)	0.43
" In study 2, darbepoetin showed a U-shaped dose-response curve with maximal infarct size-reducing effect at 5μg/kg compared to the vehicle (44."	( Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. Bencsik, P; Bhandari, A; Csonka, C; Csont, T; Ferdinandy, P; Görbe, A; Holmes, CP; Kiss, K; Kocsis, GF; Murlasits, Z; Pálóczi, J; Pan, Y; Pipis, J; Sárközy, M; Shamloo, M; Szűcs, G; Woodburn, KW, 2016)	0.43
" Despite morning dosing of both drugs, ambulatory blood pressure reductions were more pronounced at nighttime than at daytime or the 24-hour average."	( Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Hinder, M; Hirschhorn, E; Ihm, SH; Langenickel, TH; Lee, HY; Pal, P; Prescott, MF; Rhee, MY; Tan, RS; Tomlinson, B; Wang, TD; Yang, F, 2017)	0.46
"Omecamtiv mecarbil dosing guided by pharmacokinetics achieved plasma concentrations associated with improved cardiac function and decreased ventricular diameter."	( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Adams, KF; Cleland, JG; Ezekowitz, JA; Felker, GM; Goudev, A; Honarpour, N; Johnston, J; Macdonald, P; Malik, FI; McMurray, JJ; Metra, M; Mitrovic, V; Monsalvo, ML; Ponikowski, P; Serpytis, P; Solomon, SD; Spinar, J; Teerlink, JR; Tomcsányi, J; Vandekerckhove, HJ; Voors, AA, 2016)	0.43
"5 and 5 μg/kg SC syncBNP followed by an additional three dogs dosed at 5 and 10 μg/kg."	( Feasibility, safety, and tolerance of subcutaneous synthetic canine B-type natriuretic peptide (syncBNP) in healthy dogs and dogs with stage B1 mitral valve disease. Oyama, MA; Solter, PF; Stern, JA; Thorn, CL, 2017)	0.46
"This study explored the impact of intensive daily dosing of atorvastatin on in-hospital N-terminal pro-B-type natriuretic peptide level, left ventricular systolic function and incidence of major adverse cardiac events in non-ST-segment elevation myocardial infarction patients."	( Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients. Dardiri, M; Samir, A; Shehata, M, 2017)	0.46
" Repeated measurements of LVEF, troponin T and NT-proBNP and dosing records of anthracyclines and trastuzumab were available from a previously published clinical trial."	( Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Boekhout, AH; Burylo, AM; de Vries Schultink, AHM; Dorlo, TPC; Gietema, JA; Huitema, ADR; Schellens, JHM; van Hasselt, JGC, 2018)	0.48
" Furthermore, the dosage forms and dose of the pesticide, and the interval between pesticide taking and doctor visit were compared between these two groups."	( Manifestations of and risk factors for acute myocardial injury after acute organophosphorus pesticide poisoning. Chen, KX; Sun, CA; Yan, PX; Zhou, XH, 2019)	0.51
" The purified rNT-proBNP was detected by enzyme-linked immunosorbent assay and chemiluminescence enzyme immunoassay using commercial monoclonal antibodies recognizing different epitopes, showing a linear dose-response relationship in the range of tested concentrations (slope = 3."	( High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli. Ahn, J; Jeon, WY; Karisa, N; Kim, YC; Kim, YS; Lee, H, 2019)	0.51
" We aimed to assess the dose-response effect of neladenoson bialanate on cardiac structure and function, clinical outcome, and safety in patients with heart failure (HF) with reduced ejection fraction (HFrEF)."	( Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. Bax, JJ; Butler, J; Ferreira, AC; Hernandez, AF; Pap, AF; Senni, M; van der Laan, M; Voors, AA; Wirtz, AB, 2019)	0.51
" To obtain greater sensitivity the dosage of natriuretic peptides, Bioelectrical Impedance Analysis (BIA) and, more recently, Lung Ultra-Sound (LUS) can all be used."	( [Different methods to manage dry weight in hemodialysis patients]. Cupisti, A; D'Alessandro, C; Egidi, MF; Giannese, D; Puntoni, A; Varricchio, E, 2020)	0.56
"Twenty-four HD patients underwent LUS and BNP dosage at the end of the mid-week HD session, monthly for 6 months ."	( Lung ultrasound and BNP to detect hidden pulmonary congestion in euvolemic hemodialysis patients: a single centre experience. Cupisti, A; D'Alessandro, C; Egidi, MF; Giannese, D; Mannucci, C; Morganti, R; Puntoni, A; Serio, P; Varricchio, E, 2021)	0.62
" Tous avaient un dosage du BNP et ont été suivis pendant six mois."	( Prognostic Significance of Pre-Discharge Plasma BNP among Heart Failure Patients in Ilorin, Nigeria. Bello, HS; Dele-Ojo, BF; Gbadamosi, MS; Katibi, IA; Kolo, PM; Ogunmodede, JA; Omotoso, AB, 2021)	0.62
" Thus, it is important to consider the dosage and timing of dexamethasone introduction on a patient-severity basis."	( Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement. Agbulut, O; Audard, V; Bézard, M; Damy, T; Galat, A; Gilles, F; Guendouz, S; Hamon, D; Kharoubi, M; Kordeli, E; Le Bras, F; Lemonnier, F; Molinier-Frenkel, V; Oghina, S; Poullot, E; Shourick, J; Teiger, E; Vitiello, D; Zaroui, A, 2021)	0.62
" During the first 2 weeks, the dosage was titrated according to systolic blood pressure (SBP)."	( 3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function. Blom, NA; Harteveld, LM; Hazekamp, MG; Kuipers, IM; Rammeloo, LAJ; Ten Harkel, ADJ; Terol Espinosa de Los Monteros, C; van Dijk, JG, 2022)	0.72
" The distribution of steady-state doses in VICTORIA was similar across CL/F quartiles, suggesting that the ability to reach and maintain dosing at the target 10-mg dose was not related to vericiguat exposure."	( Population Pharmacokinetics of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: An Integrated Analysis. Armstrong, PW; Arrington, L; Becker, C; Blaustein, RO; Gheyas, F; Meyer, M; Passarell, J; Patel, Y; Trujillo, ME; Wenning, L, 2022)	0.72
"Conclusions: The most significant for clinical and prognostic assessment of the post-infarction period complicated by decompensated HF is the response of the patient's body to dosed physical exertion and the levels of NT-prpBNP, copeptin and ST2."	( MARKER DIAGNOSTIC HEART FAILURE PROGRESSION IN THE POST-INFARCTION PERIOD. Levandovska, KV; Naluzhna, TV; Vakaliuk, IP, 2022)	0.72
" Elevated PAGln levels were independently associated with a higher risk of the primary endpoint in a dose-response manner, regardless of HF subtype."	( Increased circulating phenylacetylglutamine concentration elevates the predictive value of cardiovascular event risk in heart failure patients. Chen, C; Huang, J; Li, C; Peng, L; Song, Y; Sun, Y; Wang, DW; Wang, H; Wei, H; Wu, J; Xiao, L; Zhang, Y; Zhao, C; Zhou, Z, 2023)	0.91
"The literature recognizes the dosage of BNP/NT-proBNP as the gold stan-dard for diagnosing HF."	( The role of laboratory medicine in a value-based healthcare system: the example of heart failure patient management in the Italian context. Aspromonte, N; Banfi, G; Barocci, S; Bartolucci, D; Chiani, V; Clerico, A; Fasano, T; Gallucci, F; Gnerre, P; Lo Sasso, B; Mariottini, A; Medea, G; Paolini, D; Pecoraro, V; Perrone, MA; Ruscio, M; Sciacovelli, L; Trenti, T, 2023)	0.91

Class	Description
polypeptide	A peptide containing ten or more amino acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Atrial natriuretic peptide receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0060	0.0060	0.0210	0.0360	AID551695
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cGMP biosynthetic process	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
cell surface receptor signaling pathway	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
receptor guanylyl cyclase signaling pathway	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
body fluid secretion	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
regulation of blood pressure	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
positive regulation of cGMP-mediated signaling	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
negative regulation of angiogenesis	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
cGMP-mediated signaling	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
negative regulation of cell growth	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
positive regulation of urine volume	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
positive regulation of renal sodium excretion	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
dopamine metabolic process	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
regulation of vascular permeability	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
blood vessel diameter maintenance	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
guanylate cyclase activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
protein kinase activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
ATP binding	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
GTP binding	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
G protein-coupled peptide receptor activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
natriuretic peptide receptor activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
peptide hormone binding	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
hormone binding	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
peptide receptor activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
adenylate cyclase activity	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
ANPR-A receptor complex	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
receptor complex	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
plasma membrane	Atrial natriuretic peptide receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID551695	Displacement of [125I]ANP from NPR-A expressed in HeLa cells after 3 hrs by gamma counting	2011	Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2	Intramolecular azo-bridge as a cystine disulfide bond surrogate: Somatostatin-14 and brain natriuretic peptide (BNP) analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	38 (0.24)	18.7374
1990's	807 (5.16)	18.2507
2000's	5146 (32.90)	29.6817
2010's	7477 (47.81)	24.3611
2020's	2172 (13.89)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,867 (11.44%)	5.53%
Reviews	1,649 (10.11%)	6.00%
Case Studies	342 (2.10%)	4.05%
Observational	590 (3.62%)	0.25%
Other	11,869 (72.74%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (81)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
B-type Natriuretic Peptide Affects the Initial Response to Intravenous Glucose in a Placebo-controlled Cross-over Study in Healthy Volunteers [NCT01324739]		10 participants (Actual)	Interventional	2010-05-31	Completed
The Relationship Between Urine Metanephrine Concentration and Myocardial and Lung Injury in Subarachnoid Haemorrhage Patients: a Prospective Observational Study [NCT05408988]		30 participants (Anticipated)	Observational	2022-01-22	Recruiting
Pulmonary Echography and BNP Value Pre- and Post- Elective Cesarean Section in Spinal Anesthesia [NCT03851679]		80 participants (Actual)	Observational	2016-12-17	Completed
Hemodynamic Effects of Nesiritide on Congestive Heart Failure Patients Receiving Mechanical Ventilation: A Prospective Observational Study [NCT04455477]		30 participants (Anticipated)	Observational	2020-05-14	Recruiting
Testosterone Regulation of the Natriuretic Peptide System [NCT02269072]		0 participants (Actual)	Interventional	2015-02-28	Withdrawn(stopped due to Lack of funding)
Assessment of the Impact of Selected Factors on the Cardiovascular System in Patients With Different Chronic Kidney Disease Stages [NCT05214872]		252 participants (Actual)	Observational	2016-03-25	Completed
Prospective Cohort Evaluation of Cardiac Function With Echocardiography and Serum B-type Natriuretic Peptide (BNP) in Obstetrical Patients With and Without a History of Cardiac Disease [NCT00759733]		0 participants (Actual)	Observational	2008-07-31	Withdrawn(stopped due to No participants enrolled)
A Randomized, Double Blinded Placebo Controlled Cross-over Study of Low Dose B-type Natriuretic Peptide (Nesiritide) With or Without Concomitant Phosphodiesterase V (PDE V) Inhibition(Sildenafil) in Congestive Heart Failure Patients With Renal Dysfunction [NCT00818701]	Phase 1	1 participants (Actual)	Interventional	2009-02-28	Terminated(stopped due to started a NIH study that is competing for same subjects)
Metabolic Effects of Natriuretic Peptide Hormones [NCT03397966]	Phase 4	5 participants (Actual)	Interventional	2018-07-01	Terminated(stopped due to Study drug no longer available)
Clinical Proteomics and Protein Therapeutics in Human Hypertension (BNP in Human Hypertension - Phase 1) [NCT00953472]	Phase 1	8 participants (Anticipated)	Interventional	2009-02-28	Terminated
Natriuretic Peptides and Metabolic Risk in Obesity [NCT02642523]	Early Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Preliminary data run on rat samples showed that this study question and design would not produce conclusive results. The PI decided not to carry out the study.)
Evaluation of Resuscitation Markers in Trauma Patients [NCT02772653]		66 participants (Actual)	Observational	2016-05-31	Completed
Evaluation of Synergy Between Natrecor and Furosemide on Renal and Neurohormone Responses in Chronic Heart Failure: A Phase-IV Study [NCT00652652]	Phase 4	0 participants	Interventional	2003-03-31	Completed
A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Nesiritide Infusion, Initiated Post-Induction of Anesthesia, in the Management of Coronary Artery Bypass Graft (CABG) Patients Requiring CardioPulmonary Bypass (CPB) [NCT00653042]	Phase 2	305 participants (Actual)	Interventional	2004-03-31	Completed
Efficacy of Intra-renal Infusion of BNP in Enhancing Renal Function in Human CHF With Cardiorenal Syndrome: A Pilot Study [NCT00348556]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2005-12-31	Terminated(stopped due to Company providing catheter bought out, funding and supplies terminated)
To Define in Human Preclinical Systolic Dysfunction (PSD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal, and Humoral Function and on the Integrated Response to Acute Sodium Loading [NCT00405639]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2006-06-30	Completed
An Exploratory Study of JNS004 (Nesiritide) in Patients With Acute Heart Failure (J2) [NCT00490724]	Phase 2	67 participants (Actual)	Interventional	2007-03-31	Completed
Specific Aims 3: Define in Hospitalized Decompensated CHF Patients With Renal Dysfunction, the Renal Actions of Low Dose Intravenous Infusion of BNP in the Presence and Absence of Acute PDE V Inhibition in Improving Renal Function [NCT00972569]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2009-10-31	Completed
Nesiritide as an Adjunctive Therapy for Children With Dilated Cardiomyopathy Admitted to the Intensive Care Unit [NCT00709163]		20 participants (Actual)	Interventional	2003-12-31	Completed
An Open-label, Single Arm, Multi-centered Clinical Trial on the Hemodynamics and Safety of Nesiritide in the Treatment of Patients With Acute Decompensate Heart Failure [NCT00813202]	Phase 3	41 participants (Actual)	Interventional	2006-10-31	Completed
Screening of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): Rationale and Design of a Multicenter, Cross-sectional Study [NCT04019600]		200 participants (Anticipated)	Observational [Patient Registry]	2019-12-23	Suspended(stopped due to Recruitment in out-patient clinic has been suspended due to COVID-19 pandemic)
Acutely Decompensated Heart Failure in a County Emergency Department: A Double Blind Randomized Controlled Comparison of Nesiritide vs. Placebo Treatment [NCT00559338]	Phase 4	104 participants (Actual)	Interventional	2003-12-31	Completed
Role of Natriuretic Peptides in the Treatment of Acutely Decompensated Heart Failure Patient With Obstructive Airways Disease [NCT00562692]	Phase 3	6 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Recruitment very difficult. Study drug expired so we have stopped the study.)
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (ASCEND-HF) [NCT00475852]	Phase 3	7,141 participants (Actual)	Interventional	2007-05-31	Completed
Investigation of the Use of Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC [NCT00338455]	Phase 2	16 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to DSMC acknowledged no safety concerns with the trial, recommending that the trial be terminated due to slow enrollment)
Acute Effect of Recombinant Human Brain Natriuretic Peptide in Patients With Pulmonary Hypertension Associated With Acute Exacerbation of Chronic Pulmonary Disease [NCT02742909]	Phase 4	9 participants (Actual)	Interventional	2015-12-31	Completed
Therapeutic Effects of BNP in Hypertensive Patients [NCT02608996]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy [NCT00252187]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2000-01-31	Completed
Nesiritide Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction [NCT00573144]	Phase 2	59 participants (Actual)	Interventional	2006-09-30	Completed
To Define in Human Preclinical Diastolic Dysfunction (PDD) the Actions of Chronic Administration of Subcutaneous (SQ) BNP on the Left Ventricular, Renal and Humoral Function and on the Integrated Response to Acute Sodium Loading [NCT00405548]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2008-03-31	Completed
Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT) [NCT00206856]	Phase 4	720 participants	Interventional	2003-07-31	Terminated(stopped due to Slow enrollment)
Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot [NCT01941576]		120 participants (Actual)	Interventional	2013-09-01	Completed
Nesiritide and Vo2 Max in Heart Failure Patients [NCT00240084]	Phase 2	20 participants (Actual)	Interventional	2003-07-31	Completed
BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects [NCT01977859]	Phase 1	4 participants (Actual)	Interventional	2013-11-30	Completed
Impact of Empiric Nesiritide or Milrinone Infusion on Early Postoperative Recovery Following Fontan Surgery: a Randomized, Double-blind, Placebo-controlled Clinical Trial [NCT00543309]	Phase 2	106 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to DSMB recommended termination based on interim outcomes analysis)
A Single-center, Pharmacokinetic Evaluation of Nesiritide in the Pediatric Population With Heart Failure [NCT00166010]		0 participants (Actual)	Interventional	2004-10-31	Withdrawn(stopped due to Observational study that DSMB placed on hold (withdrew 4 subjects). Protocol revised and received IND to become interventional PK study (no subjects enrolled).)
BNP as Adjuvant Therapy to Preserve Renal Function and Facilitate Diuresis in Hospitalized Patients With Heart Failure [NCT00170183]	Phase 3	104 participants (Anticipated)	Interventional	2003-03-31	Completed
Acute Responses in Diastolic Heart Failure [NCT00204945]		15 participants (Actual)	Interventional	2005-02-28	Completed
B-type Natriuretic Peptide for Cardio-Renal Decompensation Syndrome [NCT00186329]	Phase 4	100 participants	Interventional	2004-03-31	Completed
BNP Therapy Observation Unit Outcomes STudy [NCT00453453]	Phase 4	17 participants (Actual)	Interventional	2007-03-31	Terminated
B-natriuretic Peptide (BNP), Serum Troponin-I, and D-dimer as Risk Factors for In-hospital Death in Patients With COVID-19 [NCT04433026]		90 participants (Anticipated)	Observational	2020-08-31	Not yet recruiting
Double Blind Randomized Placebo Controlled Trial of Natrecor in Patients Hospitalized for Decompensated Heart Failure in the Presence of a Normal Left Ventricular Ejection Fraction [NCT00505791]	Phase 4	0 participants (Actual)	Interventional	2007-08-31	Withdrawn(stopped due to Unable to enroll patients)
A Double-Blind, Randomized, Placebo-Controlled Study of Nesiritide Administered After Induction of Anesthesia in Heart Failure Patients With Renal Insufficiency Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (NAPA-CS) [NCT00530361]	Phase 3	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study was withdrawn prior to patient dosing based on a business decision.)
Management of Patients With CHF After Hospitalization-Follow up Serial Infusions of NATRECOR (Nesiritide) - FUSION I, A Pilot Study [NCT00270361]	Phase 3	214 participants (Actual)	Interventional	2001-12-31	Completed
Natrecor (Nesiritide) Versus Dobutamine Therapy for Symptomatic, Decompensated CHF: A Safety Study Using 24-Hour Holter Monitoring - The PRECEDENT Trial: Prospective, Randomized Evaluation of Cardiac Ectopy With Dobutamine or Natrecor Therapy [NCT00270400]	Phase 3	255 participants (Actual)	Interventional	1998-08-31	Completed
Renal Effects of Intrarenal Nesiritide [NCT00270829]	Phase 4	2 participants (Actual)	Interventional	2005-12-31	Terminated(stopped due to Funding not available)
Phase IV, Open Labeled Study to Test the Effectiveness of Nesiritide in Reversing Pulmonary Hypertension in Patients Who Will be Undergoing CardioThoracic Surgery [NCT00075179]	Phase 4	15 participants (Actual)	Interventional	2003-12-31	Terminated(stopped due to Low accrual.)
A Randomized, Double-Blinded, Placebo-Controlled Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in Subjects With Decompensated CHF [NCT00288730]	Phase 3	127 participants (Actual)	Interventional	1996-10-31	Completed
Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction [NCT00119691]	Phase 2	34 participants (Actual)	Interventional	2003-04-30	Completed
Follow-up Serial Infusions of Natrecor(Nesiritide) in the Management of Patients With Heart Failure-FUSION II [NCT00091520]	Phase 2	920 participants (Actual)	Interventional	2004-04-30	Completed
Prophylactic Use of Nesiritide (Brain Natriuretic Peptide, BNP) for the Prevention of Acute Renal Failure in Thoracic Aortic Aneurysm Surgery Patients [NCT00110201]	Phase 3	124 participants	Interventional	2005-03-31	Recruiting
The Effect of Aortic Impedance on Myocardial Relaxation [NCT00204984]		17 participants (Actual)	Interventional	2005-05-31	Completed
Natrecor® (Nesiritide) as a Nitric Oxide Sparing Agent in Patients Undergoing Lung Transplantation [NCT00205426]	Phase 4	7 participants (Actual)	Interventional	2005-08-31	Completed
Continuous Infusion Nesiritide in Chronic Heart Failure-University of Chicago (CINCH-UC) [NCT00145873]	Phase 2	20 participants	Interventional	2003-08-31	Terminated(stopped due to Unable to complete study)
The Use of Nesiritide in the Management of Acute Diastolic Heart Failure [NCT00083772]	Phase 4	9 participants (Actual)	Interventional	2004-05-17	Terminated
Pharmacogenetics of Ace Inhibitor-Associated Angioedema:Aim 1 [NCT01413542]		44 participants (Actual)	Interventional	2011-11-30	Completed
PET/MR in Post Stroke Cardiac Inflammation Study [NCT05791617]		12 participants (Anticipated)	Observational	2023-07-01	Recruiting
A Randomized Controlled Trial to Evaluate Renal Function, Inflammatory Mediators, and Neurohormonal Markers in Acutely Decompensated Heart Failure Patients Receiving Nesiritide Compared to Nitroglycerin. [NCT00842023]	Phase 4	89 participants (Actual)	Interventional	2006-07-31	Completed
Low Dose Continuous Infusion of BNP (Nesiritide) in the Prevention of Renal Insufficiency Post Cardiopulmonary Bypass Cardiac Surgery. [NCT00252200]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2003-03-31	Completed
Prospective Randomized Outcomes Study of Acutely Decompensated Congestive Heart Failure Treated Initially in Outpatients With Natrecor (Nesiritide) - The PROACTION Trial [NCT00270387]	Phase 3	250 participants (Actual)	Interventional	2001-01-31	Completed
Concentration of Trimethylamine-N-oxide Versus Echocardiographic, Biochemical and Histopathological Parameters of Heart Failure in Patients With Severe Aortic Stenosis: a Prospective, Observatory Trial [NCT04406805]		70 participants (Anticipated)	Observational	2019-01-15	Recruiting
A Randomized, Open-Label, Active-Controlled, Multicenter Phase III Safety Study of Two Doses of NATRECOR hBNP (Nesiritide) Administered as a Continuous Infusion in the Treatment of Decompensated CHF [NCT00271557]	Phase 3	305 participants (Actual)	Interventional	1997-01-31	Completed
Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1 [NCT00262574]	Phase 4	500 participants (Anticipated)	Interventional	2005-07-31	Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Hemodynamic and Clinical Effects of Natrecor (Nesiritide) Compared With Nitroglycerin Therapy for Symptomatic Decompensated CHF, The VMAC Trial: Vasodilation in the Management of Acu [NCT00270374]	Phase 3	498 participants (Actual)	Interventional	1999-10-31	Completed
A Comparative Study of Advanced Imaging Techniques in Predicting the Clinical Outcome in Aortic Stenosis [NCT01775215]		0 participants (Actual)	Observational	2013-01-31	Withdrawn(stopped due to Abandoned)
Effect of rhBNP on Coronary Microcirculation in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI [NCT05723315]		160 participants (Anticipated)	Interventional	2023-02-20	Not yet recruiting
Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction [NCT04063579]		172 participants (Actual)	Interventional	2018-06-01	Completed
Pilot Study of the Effects of Nesiritide on Hemodynamics and Urine Output Following Cardiopulmonary Bypass in Infants [NCT00281671]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2006-04-08	Terminated(stopped due to Slow patient enrollment.)
Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study [NCT01132846]	Phase 2	360 participants (Actual)	Interventional	2010-08-31	Completed
To Define the Role of PDEV in Mediating the Decreased GFR and Attenuated Renal Sodium and cGMP Excretory Response to Acute Saline Volume Expansion in PSD and PDD With Renal Dysfunction. [NCT01544998]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2012-02-29	Completed
The Impact of Nesiritide on Renal Function After Implantation of the Total Artificial Heart and Left Ventricular Assist Devices [NCT01836809]	Phase 4	2 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Futility for enrollment)
Novel Peptides in Resistant Human Hypertension [NCT01514357]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Original PI left the institution, and lack of funding.)
To Define in Normal Controls, Human Preclinical Systolic Dysfunction (PSD) and Preclinical Diastolic Dysfunction (PDD) the Actions of Acute Subcutaneous Nesiritide (BNP) on the Cardiorenal and Humoral Function and the Integrated Response to Acute Sodium L [NCT00387621]	Phase 1/Phase 2	58 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized, Single-Blind, Placebo-Controlled, Single-Center Clinical Study of the Efficacy and Safety of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children [NCT03207295]		108 participants (Anticipated)	Interventional	2017-07-05	Recruiting
Does Nesiritide Provide Renal Protection By Attenuating the Inflammatory Response [NCT01440881]	Phase 2	37 participants (Actual)	Interventional	2010-04-30	Completed
A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study on the Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Improving Type 3 Pulmonary Hypertension. [NCT05716984]	Phase 4	72 participants (Anticipated)	Interventional	2023-04-15	Enrolling by invitation
Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: Brain Natriuretic Peptide Levels Versus the Clinical Congestion Score [NCT00484770]	Phase 2	135 participants (Actual)	Interventional	2003-02-28	Completed
Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure [NCT05111769]		70 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis [NCT03377465]		100 participants (Actual)	Interventional	2016-11-15	Completed
Incidence and Clinical Relevance of Perioperative Elevation of Troponin I and N- Terminal Pro-Brain Natriuretic Peptide in Patients Undergoing Lung Resection [NCT04749212]		345 participants (Anticipated)	Observational	2021-05-19	Recruiting
Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects [NCT03234751]	Phase 1	6 participants (Actual)	Interventional	2017-07-13	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00252187 (8) [back to overview]	Change in Left Ventricular (LV) Volume Index at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Blood Pressure at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Plasma Renin Activity at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Left Ventricular Ejection Fraction at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Left Ventricular (LV) Mass Index at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Heart Rate at 8 Weeks
NCT00252187 (8) [back to overview]	Change in Left Ventricular (LV) Filling Pressure at 8 Weeks
NCT00281671 (4) [back to overview]	Number of Participants With Hypotension and Bradycardia
NCT00281671 (4) [back to overview]	Urine Output
NCT00281671 (4) [back to overview]	Urine Output
NCT00281671 (4) [back to overview]	Cardiac Index
NCT00387621 (10) [back to overview]	Change in Natriuresis (Urinary Sodium Excretion) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment
NCT00387621 (10) [back to overview]	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment
NCT00387621 (10) [back to overview]	Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment
NCT00387621 (10) [back to overview]	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment
NCT00387621 (10) [back to overview]	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment
NCT00387621 (10) [back to overview]	Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment
NCT00387621 (10) [back to overview]	Nesiritide Pre-Treatment Urinary cGMP Excretion After Volume Expansion (UcGMPV)
NCT00387621 (10) [back to overview]	Nesiritide Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UNaV)
NCT00387621 (10) [back to overview]	Placebo Pre-Treatment Urinary cGMP Excretion After Volume Expansion (UcGMPV)
NCT00387621 (10) [back to overview]	Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV)
NCT00405548 (4) [back to overview]	Left Ventricular (LV) Filling Pressure
NCT00405548 (4) [back to overview]	Change in Urinary Sodium Excretion in Response to Saline Load
NCT00405548 (4) [back to overview]	Change in Urinary Flow in Response to Saline Load
NCT00405548 (4) [back to overview]	Change in Glomerular Filtration Rate (GFR) in Response to Saline Load
NCT00405639 (4) [back to overview]	Change in Left Ventricular Mass Index
NCT00405639 (4) [back to overview]	Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) in Response to Saline Load
NCT00405639 (4) [back to overview]	Change in Urinary Sodium Excretion in Response to Saline Load
NCT00405639 (4) [back to overview]	Change in Urine Flow in Response to Saline Load
NCT00475852 (12) [back to overview]	Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality
NCT00475852 (12) [back to overview]	Number of Days Alive and Outside the Hospital
NCT00475852 (12) [back to overview]	Number of Patients With Renal Impairment
NCT00475852 (12) [back to overview]	Cardiovascular Mortality Through Day 30
NCT00475852 (12) [back to overview]	Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug
NCT00475852 (12) [back to overview]	Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug
NCT00475852 (12) [back to overview]	Overall Well-Being Self-Assessment at 24 Hours After Initiation of Study Drug
NCT00475852 (12) [back to overview]	Overall Well-Being Self-Assessment at 6 Hours After Initiation of Study Drug
NCT00475852 (12) [back to overview]	Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality
NCT00475852 (12) [back to overview]	All-Cause Mortality Through Day 180
NCT00475852 (12) [back to overview]	All-Cause Mortality Through Day 30
NCT00475852 (12) [back to overview]	Composite of Persistent or Worsening Heart Failure and All-Cause Mortality
NCT00490724 (20) [back to overview]	Number of Participants With Dyspnea Symptoms Assessed by Borg Scale Score
NCT00490724 (20) [back to overview]	Change From Baseline in Systemic Vascular Resistance (SVR) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Stroke Volume Index (SVI) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Stroke Volume (SV) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Pulmonary Vascular Resistance (PVR) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP or Pulmonary Arterial Diastolic Pressure[PADP]) at 3 Hours
NCT00490724 (20) [back to overview]	Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Pulmonary Arterial Diastolic Pressure (PADP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Mean Right Atrial Pressure (MRAP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Mean Pulmonary Arterial Pressure (MPAP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Mean Blood Pressure (MBP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24 Hour
NCT00490724 (20) [back to overview]	Assessment of Dyspnea Using Respiratory Rate
NCT00490724 (20) [back to overview]	Change From Baseline in Cardiac Output (CO) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Change From Baseline in Cardiac Index (CI) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour
NCT00490724 (20) [back to overview]	Assessment of Dyspnea Using Percutaneous Arterial Oxygen Saturation (SpO2)
NCT00490724 (20) [back to overview]	Number of Participants With Oxygen Therapy
NCT00490724 (20) [back to overview]	Urinary Volume
NCT00490724 (20) [back to overview]	Number of Participants With Orthopnea
NCT00490724 (20) [back to overview]	Number of Participants With Dyspnea Symptoms Assessed by Likert Scale Score
NCT00543309 (15) [back to overview]	Resource Utilization: Days Alive and Out of Hospital Within 180 Days of Surgery
NCT00543309 (15) [back to overview]	Resource Utilization: Days of Initial CICU Stay
NCT00543309 (15) [back to overview]	Resource Utilization: Hours of Mechanical Ventilation Until Initial Extubation
NCT00543309 (15) [back to overview]	Epinephrine Levels
NCT00543309 (15) [back to overview]	N-terminal Pro-brain Natriuretic Peptide Levels
NCT00543309 (15) [back to overview]	Plasma Norepinephrine Levels.
NCT00543309 (15) [back to overview]	Cardiovascular: Arrhythmia
NCT00543309 (15) [back to overview]	Cardiovascular: Cardiac Index
NCT00543309 (15) [back to overview]	Cardiovascular: Cardiac Index
NCT00543309 (15) [back to overview]	Cardiovascular: Peak Inotrope Score
NCT00543309 (15) [back to overview]	Cardiovascular: Peak Lactate Level
NCT00543309 (15) [back to overview]	Days Alive and Out of the Hospital Within 30 Days of Surgery.
NCT00543309 (15) [back to overview]	Renal Function: Maximum Change in Serum Creatinine
NCT00543309 (15) [back to overview]	Renal Function: Urine Output
NCT00543309 (15) [back to overview]	Resource Utilization: Chest Tube Days
NCT00573144 (3) [back to overview]	Change in Left Ventricular End-Systolic Volume Index
NCT00573144 (3) [back to overview]	Change in Left Ventricular End-Systolic Diastolic Volume Index
NCT00573144 (3) [back to overview]	Myocardial Infarct Size at 30 Days
NCT00842023 (3) [back to overview]	Inflammatory Markers
NCT00842023 (3) [back to overview]	Renal Function by Serum Creatinine
NCT00842023 (3) [back to overview]	Serum Levels of Cystatin-C
NCT01132846 (15) [back to overview]	Change in Blood Urea Nitrogen (BUN)/ Serum Cystatin C Ratio
NCT01132846 (15) [back to overview]	Change in Clinical Stability- RED-ROSE
NCT01132846 (15) [back to overview]	Change in Cystatin C
NCT01132846 (15) [back to overview]	Change in Dyspnea Assessment (RED-ROSE Substudy)
NCT01132846 (15) [back to overview]	Change in Heart Failure Status
NCT01132846 (15) [back to overview]	Change in Serum Creatinine
NCT01132846 (15) [back to overview]	Change in Treatment Response
NCT01132846 (15) [back to overview]	Change in Weight
NCT01132846 (15) [back to overview]	Cumulative Urinary Sodium Excretion
NCT01132846 (15) [back to overview]	Cumulative Urinary Volume
NCT01132846 (15) [back to overview]	Decongestive Changes- RED-ROSE
NCT01132846 (15) [back to overview]	Development of Cardio-renal Syndrome
NCT01132846 (15) [back to overview]	Dyspnea Visual Analog Scale Area Under the Curve
NCT01132846 (15) [back to overview]	Global Visual Analog Scale Area Under the Curve
NCT01132846 (15) [back to overview]	Worst Reported Symptom Changes-RED-ROSE
NCT01413542 (5) [back to overview]	Assess Effect of ACE and/or DPP4 Inhibition on Heart Rate Response to Substance P (SP)
NCT01413542 (5) [back to overview]	Assess Tissue Type Plasminogen Activator (tPA) Release
NCT01413542 (5) [back to overview]	Effect of Treatment (ACE or DPP4 Inhibition, or Combined) on Norepinephrine (NE) Release (Arterial Venous Gradient) in Response to Substance P (SP)
NCT01413542 (5) [back to overview]	Effect of Treatment (DPP4 Inhibition vs. Placebo) on Venous GLP-1 Levels in Response to Arterial GLP-1 Infusion
NCT01413542 (5) [back to overview]	The Effect of Enalaprilat (ACE Inhibition), Sitagliptin (DPP4 Inhibition), or the Combination on the Vasodilator Response (Forearm Blood Flow) to Substance P (SP) and Bradykinin (Group 1) or Glucagon Like Peptide-1 and Brain Naturetic Peptide (Group 2).
NCT01440881 (4) [back to overview]	The Examine and Measure Endothelin-1 to Measure Kidney Injury
NCT01440881 (4) [back to overview]	The Examine and Measure Urinary NGAL to Measure Kidney Injury
NCT01440881 (4) [back to overview]	Measure Neutrophils to Measure Kidney Injury
NCT01440881 (4) [back to overview]	The Examine and Measure Cytokines to Measure Kidney Injury
NCT01514357 (1) [back to overview]	Changes in Systolic Blood Pressure (BP)
NCT01544998 (6) [back to overview]	Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group
NCT01544998 (6) [back to overview]	Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group
NCT01544998 (6) [back to overview]	Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group
NCT01544998 (6) [back to overview]	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Diastolic Dysfunction (PDD) Reporting Group
NCT01544998 (6) [back to overview]	Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group
NCT01544998 (6) [back to overview]	Change in Glomerular Filtration Rate (GFR) at 60 Minutes for Preclinical Systolic Dysfunction (PSD) Reporting Group
NCT03397966 (2) [back to overview]	Change in Resting Energy Expenditure (EE)
NCT03397966 (2) [back to overview]	Adipose Tissue Gene Expression of Uncoupling Protein 1 (UCP1)

Change in Left Ventricular (LV) Volume Index at 8 Weeks

LV volume was measured for systolic volume and diastolic volume using a cardiac Magnetic Resonance Imaging (MRI) scan. All cardiac MRI images were reviewed by an independent cardiologist in a blinded fashion. (NCT00252187)
Timeframe: Baseline and 8 weeks

Intervention	ml/m^2 (Mean)
	End-systolic LV volume index	End-diastolic LV volume index
B-type Natriuretic Peptide (BNP)	-5.2	-10.0
Placebo	5.8	6.1

Intervention	mmHg (Mean)
	Change in systolic blood pressure	Change in diastolic blood pressure
B-type Natriuretic Peptide (BNP)	-4.9	-2.4
Placebo	4.5	0.9

Intervention	L/min/m^2 (Median)
	baseline	6 hours after onset of drug infusion
Nesiritide	1.90	2.15
Placebo	1.83	1.95

Intervention	mEq/min (Mean)
Control	440.93
PSD-Preclinical Systolic Dysfunction	261.07
PDD-Preclinical Diastolic Dysfunction	242.82

Intervention	pmol/min (Mean)
Control	303.32
PSD-Preclinical Systolic Dysfunction	384.62
PDD-Preclinical Diastolic Dysfunction	335.29

Intervention	pmol/min (Mean)
Control	244.69
PSD-Preclinical Systolic Dysfunction	255.31
PDD-Preclinical Diastolic Dysfunction	353.37

Intervention	mEq/min (Mean)
Control	183.83
PSD-Preclinical Systolic Dysfunction	226.89
PDD-Preclinical Diastolic Dysfunction	41.55

Intervention	pmol/min (Mean)
	Urinary cGMP Excretion (Baseline/Pretreatment)	Urinary cGMP Excretion at 30 min	Urinary cGMP Excretion at 60 min
Control Group (Normals)	130.8	399.6	508.4
Preclinical Diastolic Dysfunction Group (PDD)	258.0	487.8	475.0
Preclinical Systolic Dysfunction Group (PSD)	192.2	388.6	518.7

Intervention	uEq/min (Mean)
	Urinary Sodium Excretion (Baseline/Pre-treatment)	Urinary Sodium Excretion at 30 min	Urinary Sodium Excretion at 60 min
Control Group (Normals)	183.9	393.4	650.1
Preclinical Diastolic Dysfunction Group (PDD)	219.1	303.2	464.8
Preclinical Systolic Dysfunction Group (PSD)	232.6	314.7	469.4

Intervention	pmol/min (Mean)
	Urinary cGMP Excretion (Baseline/Pre-treatment)	Urinary cGMP Excretion at 30 min	Urinary cGMP Excretion at 60 min
Control Group (Normals)	97.8	154.9	196.0
Preclinical Diastolic Dysfunction Group (PDD)	245.8	134.4	139.7
Preclinical Systolic Dysfunction Group (PSD)	219.5	133.3	134.1

Intervention	E/e' (Mean)
	Baseline LV Filling Pressure	12 Week LV Filling Pressure
BNP (Nesiritide)	14.9	12.6
Placebo	14.9	14.0

Intervention	nanograms per milliliter per hour (Mean)
B-type Natriuretic Peptide (BNP)	-3.5
Placebo	2.3

Intervention	Participants (Number)
	Total Cardiovascular Deaths	Worsening Heart Failure	Myocardial Infarction	Sudden Cardiac Death	Other Cardiovascular Cause	Presumed Cardiovascular Cause
Nesiritide	112	68	4	20	11	9
Placebo	124	80	0	23	10	11

Intervention	Participants (Number)
	Markedly Better	Moderately Better	Minimally Better	No Change	Minimally Worse	Moderately Worse	Markedly Worse
Nesiritide	1025	1274	716	291	27	7	31
Placebo	935	1313	751	323	36	15	25

Intervention	Participants (Number)
	Baseline:Score 0; at 1 hour:Score 0	Baseline:Score 0.5; at 1 hour:Score 1	Baseline:Score 1; at 1 hour:Score 0	Baseline:Score 1; at 1 hour:Score 1	Baseline:Score 1; at 1 hour:Score 2	Baseline:Score 2; at 1 hour:Score 0	Baseline:Score 2; at 1 hour:Score 0.5	Baseline:Score 2; at 1 hour:Score 1	Baseline:Score 2; at 1 hour:Score 2	Baseline:Score 3; at 1 hour:Score 1	Baseline:Score 3; at 1 hour:Score 2	Baseline:Score 3; at 1 hour:Score 3	Baseline:Score 4; at 1 hour:Score 3	Baseline:Score 4; at 1 hour:Score 4	Baseline:Score 5; at 1 hour:Score 3	Baseline:Score 5; at 1 hour:Score 4	Baseline:Score 5; at 1 hour:Score 5	Baseline:Score 6; at 1 hour:Score 1	Baseline:Score 6; at 1 hour:Score 3	Baseline:Score 7; at 1 hour:Score 0	Baseline:Score 7; at 1 hour:Score 2	Baseline:Score 7; at 1 hour:Score 3	Baseline:Score 7; at 1 hour:Score 7	Baseline:Score 8; at 1 hour:Score 3	Baseline:Score 9; at 1 hour:Score 3	Baseline:Score 9; at 1 hour:Score 4	Baseline:Score 10; at 1 hour:Score 4	Baseline:Score 0; at 24 hour:Score 0	Baseline:Score 0; at 24 hour:Score 1	Baseline:Score 0.5; at 24 hour:Score 1	Baseline:Score 1; at 24 hour:Score 0	Baseline:Score 1; at 24 hour:Score 1	Baseline:Score 2; at 24 hour:Score 0	Baseline:Score 2; at 24 hour:Score 0.5	Baseline:Score 2; at 24 hour:Score 1	Baseline:Score 2; at 24 hour:Score 2	Baseline:Score 3; at 24 hour:Score 0	Baseline:Score 3; at 24 hour:Score 0.5	Baseline:Score 3; at 24 hour:Score 1	Baseline:Score 3; at 24 hour:Score 2	Baseline:Score 4; at 24 hour:Score 0	Baseline:Score 4; at 24 hour:Score 0.5	Baseline:Score 4; at 24 hour:Score 1	Baseline:Score 4; at 24 hour:Score 3	Baseline:Score 5; at 24 hour:Score 0	Baseline:Score 5; at 24 hour:Score 1	Baseline:Score 5; at 24 hour:Score 2	Baseline:Score 6; at 24 hour:Score 0	Baseline:Score 6; at 24 hour:Score 3	Baseline:Score 7; at 24 hour:Score 0	Baseline:Score 7; at 24 hour:Score 1	Baseline:Score 7; at 24 hour:Score 3	Baseline:Score 7; at 24 hour:Score 4	Baseline:Score 8; at 24 hour:Score 1
Nesiritide (1+ 0.01)	1	0	1	0	0	0	0	1	2	0	2	1	1	1	0	0	0	0	0	0	1	1	1	2	1	1	0	1	0	0	1	0	0	1	0	1	1	1	2	0	1	0	0	0	0	0	0	0	0	0	1	1	0	2
Nesiritide (2+0.005)	2	1	1	1	2	1	1	1	0	1	2	0	1	1	0	1	1	1	0	0	0	1	0	0	0	0	1	2	0	1	1	3	1	0	1	1	0	0	1	1	0	1	1	0	1	0	1	1	0	1	0	0	0	0
Nesiritide (2+0.01)	4	0	0	0	0	0	1	0	2	1	3	2	1	0	1	0	0	0	1	1	0	0	0	0	0	0	0	2	0	0	0	0	0	1	1	1	3	2	1	0	0	0	0	1	0	1	0	0	1	0	0	0	1	0

Intervention	dyne*second per centimeter^5 (Mean)
	Baseline (n=19,18,16)	Change at 0.25 hour (n=19,17,16)	Change at 0.5 hour (n=19,18,16)	Change at 1 hour (n=19,18,16)	Change at 1.5 hour (n=19,18,16)	Change at 2 hour (n=19,18,16)	Change at 2.5 hour (n=19,18,16)	Change at 3 hour (n=19,18,16)	Change at 4 hour (n=19,17,16)	Change at 5 hour (n=18,17,16)	Change at 6 hour (n=18,17,16)	Change at 12 hour (n=16,17,16)	Change at 24 hour (n=14,17,14)
Nesiritide (1+ 0.01)	1935.318	-261.453	-229.968	-265.611	-170.120	-121.127	49.262	-81.183	-18.367	40.462	0.026	157.757	-88.612
Nesiritide (2+0.005)	2170.633	-366.981	-453.601	-456.113	-328.746	-308.987	-292.112	-297.880	-339.457	-254.269	-68.635	-26.925	68.641
Nesiritide (2+0.01)	2062.369	-384.379	-686.497	-611.673	-370.457	-316.466	-220.959	-219.786	-184.293	-211.770	-189.116	-327.763	-56.456

Intervention	milliliter per meter^2 (Mean)
	Baseline (n=17,19,17)	Change at 0.25 hour (n=17,18,17)	Change at 0.5 hour (n=17,19,17)	Change at 1 hour (n=17,19,17)	Change at 1.5 hour (n=17,19,17)	Change at 2 hour (n=17,19,17)	Change at 2.5 hour n=17,19,17)	Change at 3 hour (n=17,19,17)	Change at 4 hour (n=17,18,17)	Change at 5 hour (n=16,18,17)	Change at 6 hour (n=16,18,17)	Change at 9 hour (n=0,1,0)	Change at 12 hour (n=15,18,17)	Change at 15 hour (n=2,1,0)	Change at 24 hour (n=13,18,15)
Nesiritide (1+ 0.01)	29.683	2.888	4.116	3.904	2.822	3.196	0.394	2.751	1.097	0.525	0.320	NA	1.100	-3.357	1.690
Nesiritide (2+0.005)	28.655	1.853	3.775	4.892	3.900	3.526	1.501	1.781	1.494	2.427	1.421	4.657	-0.912	-0.592	-0.808
Nesiritide (2+0.01)	24.483	2.584	9.191	8.007	4.948	3.760	3.052	2.091	3.142	4.146	3.319	NA	5.610	NA	0.590

Intervention	milliliter (ml) (Mean)
	Baseline (n=17,19,17)	Change at 0.25 hour (n=17,19,17)	Change at 0.5 hour (n=17,19,17)	Change at 1 hour (n=17,19,17)	Change at 1.5 hour (n=17,19,17)	Change at 2 hour (n=17,19,17)	Change at 2.5 hour (n=17,19,17)	Change at 3 hour (n=17,19,17)	Change at 4 hour (n=17,18,17)	Change at 5 hour (n=16,18,17)	Change at 6 hour (n=16,18,17)	Change at 9 hour (n=0,1,0)	Change at 12 hour (n=15,18,17)	Change at 15 hour (n=2,1,0)	Change at 24 hour (n=13,18,15)
Nesiritide (1+ 0.01)	48.368	4.122	6.348	6.295	4.666	6.003	0.133	4.744	1.477	0.909	-0.391	NA	1.254	-5.022	2.333
Nesiritide (2+0.005)	49.126	3.305	6.887	8.442	7.722	6.877	1.768	2.865	2.888	4.339	2.685	8.792	-1.357	-0.955	-1.421
Nesiritide (2+0.01)	41.545	3.517	15.121	13.039	8.293	6.119	5.490	2.909	5.053	6.802	5.544	NA	9.123	NA	0.448

Intervention	dyne*second/centimeter^5 (Mean)
	Baseline (n=14,18,14)	Change at 0.25 hour (n=14,17,13)	Change at 0.5 hour (n=14,18,13)	Change at 1 hour (n=14,18,12)	Change at 1.5 hour (n=14,18,12)	Change at 2 hour (n=14,18,12)	Change at 2.5 hour (n=14,18,12)	Change at 3 hour (n=14,18,12)	Change at 4 hour (n=14,17,12)	Change at 5 hour (n=12,17,12)	Change at 6 hour (n=12,17,12)	Change at 9 hour (n=0,1,0)	Change at 12 hour (n=10,17,12)	Change at 15 hour (n=1,1,0)	Change at 24 hour (n=9,17,10)
Nesiritide (1+ 0.01)	215.736	-19.361	-12.954	-0.991	19.161	11.083	32.991	6.691	12.217	30.161	50.780	NA	42.717	46.681	32.656
Nesiritide (2+0.005)	208.714	-40.647	-23.263	1.964	-2.975	23.400	11.609	-2.667	3.797	-10.958	10.104	2.017	20.625	116.667	-29.072
Nesiritide (2+0.01)	239.383	-12.482	-34.144	-44.337	-34.079	-2.991	1.610	11.381	-30.437	-21.678	-4.627	NA	-18.302	NA	-37.891

Intervention	Millimeters of Mercury (mmHg) (Mean)
	Baseline	Change at 3 hours
Nesiritide (1+ 0.01)	27.7	-6.7
Nesiritide (2+0.005)	24.8	-5.4
Nesiritide (2+0.01)	29.7	-6.2

Intervention	Millimeters of mercury (Mean)
	Baseline (n=19,20,17)	Change at 0.25 hour (n=19,19,17)	Change at 0.5 hour (n=19,20,17)	Change at 1 hour (n=19,20,17)	Change at 1.5 hour (n=19,20,17)	Change at 2 hour (n=19,20,17)	Change at 2.5 hour (n=19,20,17)	Change at 3 hour (n=19,20,17)	Change at 4 hour (n=19,19,17)	Change at 5 hour (n=18,19,17)	Change at 6 hour (n=18,19,17)	Change at 9 hour (n=0,1,0)	Change at 12 hour (n=17,19,17)	Change at 15 hour (n=2,1,0)	Change at 24 hour (n=14,19,15)
Nesiritide (1+ 0.01)	55.9	-3.6	-5.3	-7.0	-6.2	-7.2	-7.0	-9.4	-10.2	-10.0	-9.9	NA	-11.3	6.0	-9.3
Nesiritide (2+0.005)	51.3	-8.2	-8.7	-8.7	-7.6	-6.8	-5.9	-6.1	-5.7	-6.8	-6.1	13.0	-9.1	6.0	-10.4
Nesiritide (2+0.01)	59.8	-4.2	-5.5	-7.4	-8.8	-7.0	-6.6	-6.4	-7.5	-8.2	-10.1	NA	-12.7	NA	-12.2

Intervention	Breaths Per Minute (BrPM) (Mean)
	Baseline (n= 19,20,17)	At 1 hour (n= 18,20,17)	At 2 hour (n= 19,20,17)	At 3 hour (n= 19,20,17)	At 6 hour (n= 13,15,17)	At 9 hour (n= 0,1,0)	At 15 hour (n=2,1,0)	At 24 hour (n= 14,18,17)
Nesiritide (1+ 0.01)	24.7	24.0	23.2	22.7	21.2	NA	22.0	19.4
Nesiritide (2+0.005)	25.6	23.0	22.1	22.9	21.8	22.0	33.0	20.8
Nesiritide (2+0.01)	23.8	22.6	21.2	20.4	20.5	NA	NA	21.4

natriuretic peptide, brain

Description

Cross-References

Synonyms (20)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (1)

Inhibition Measurements

Biological Processes (16)

Molecular Functions (10)

Ceullar Components (3)

Bioassays (1)

Research

Studies (15,640)

Study Types

Clinical Trials (81)

Trial Overview

Trial Outcomes

Change in Left Ventricular (LV) Volume Index at 8 Weeks

Change in Blood Pressure at 8 Weeks

Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) at 8 Weeks

Change in Plasma Renin Activity at 8 Weeks

Change in Left Ventricular Ejection Fraction at 8 Weeks

Change in Left Ventricular (LV) Mass Index at 8 Weeks

Change in Heart Rate at 8 Weeks

Change in Left Ventricular (LV) Filling Pressure at 8 Weeks

Number of Participants With Hypotension and Bradycardia

Urine Output

Urine Output

Cardiac Index

Change in Natriuresis (Urinary Sodium Excretion) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment

Change in Urinary Cyclic Guanosine Monophosphate (cGMP) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment

Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment

Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment

Change in Urinary Cyclic Guanosine Monophosphate (cGMP) at 30 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment

Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes in Response to Nesiritide Treatment Compared to Placebo Treatment

Nesiritide Pre-Treatment Urinary cGMP Excretion After Volume Expansion (UcGMPV)

Nesiritide Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UNaV)

Placebo Pre-Treatment Urinary cGMP Excretion After Volume Expansion (UcGMPV)

Placebo Pre-Treatment Urinary Sodium Excretion After Volume Expansion (UnaV)

Left Ventricular (LV) Filling Pressure

Change in Urinary Sodium Excretion in Response to Saline Load

Change in Urinary Flow in Response to Saline Load

Change in Glomerular Filtration Rate (GFR) in Response to Saline Load

Change in Left Ventricular Mass Index

Change in Renal Function as Measured by Glomerular Filtration Rate (GFR) in Response to Saline Load

Change in Urinary Sodium Excretion in Response to Saline Load

Change in Urine Flow in Response to Saline Load

Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality

Number of Days Alive and Outside the Hospital

Number of Patients With Renal Impairment

Cardiovascular Mortality Through Day 30

Dyspnea Self-Assessment at 24 Hours After Initiation of Study Drug

Dyspnea Self-Assessment at 6 Hours After Initiation of Study Drug

Overall Well-Being Self-Assessment at 24 Hours After Initiation of Study Drug

Overall Well-Being Self-Assessment at 6 Hours After Initiation of Study Drug

Composite of Cardiovascular Rehospitalization and Cardiovascular Mortality

All-Cause Mortality Through Day 180

All-Cause Mortality Through Day 30

Composite of Persistent or Worsening Heart Failure and All-Cause Mortality

Number of Participants With Dyspnea Symptoms Assessed by Borg Scale Score

Change From Baseline in Systemic Vascular Resistance (SVR) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12 and 24 Hour

Change From Baseline in Stroke Volume Index (SVI) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Stroke Volume (SV) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Pulmonary Vascular Resistance (PVR) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP or Pulmonary Arterial Diastolic Pressure[PADP]) at 3 Hours

Change From Baseline in Pulmonary Arterial Systolic Pressure (PASP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Pulmonary Arterial Diastolic Pressure (PADP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Mean Right Atrial Pressure (MRAP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 15 and 24 Hour

Change From Baseline in Mean Pulmonary Arterial Pressure (MPAP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Mean Blood Pressure (MBP) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24 Hour

Assessment of Dyspnea Using Respiratory Rate

Change From Baseline in Cardiac Output (CO) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Change From Baseline in Cardiac Index (CI) at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15 and 24 Hour

Intervention	Percentage of SpO2 (Mean)
	Baseline (n=19,20,17)	At 1 hour (n=18,20,17)	At 2 hour (n=19,20,17)	At 3 hour (n=19,20,17)	At 6 hour (n=13,15,17)	At 9 hour (n=0,1,0)	At 15 hour (n=2,1,0)	At 24 hour (n=14,19,15)
Nesiritide (1+ 0.01)	96.5	96.6	96.8	96.7	97.6	NA	94.5	97.1
Nesiritide (2+0.005)	96.4	96.6	96.8	96.9	97.3	100.0	99.0	97.1
Nesiritide (2+0.01)	96.9	96.4	97.7	98.4	97.5	NA	NA	98.1

Intervention	Participants (Number)
	Baseline: 'Yes';at 1 hour 'Yes'(n=18,20,17	Baseline: 'No';at 1 hour 'No'(n=18,20,17)	Baseline: 'Yes';at 24 hour 'Yes'(n=14,19,15)	Baseline:'No';at 24 hour 'No'(n=14,19,15)
Nesiritide (1+ 0.01)	16	2	12	2
Nesiritide (2+0.005)	20	0	19	0
Nesiritide (2+0.01)	17	0	15	0

Intervention	Millliter (Mean)
	Baseline (n=15,19,15)	At 3 hour (n=19,20,17)	At 24 hour (n=19,20,17)
Nesiritide (1+ 0.01)	83.9	539.9	1976.3
Nesiritide (2+0.005)	67.0	423.6	2296.9
Nesiritide (2+0.01)	79.7	545.1	2233.6

Intervention	Participants (Number)
	Baseline: 'Yes'; at 1 hour 'Yes'	Baseline: 'Yes'; at 1 hour 'No'	Baseline: 'No'; at 1 hour 'No'	Baseline: 'Yes'; at 24 hour 'Yes'	Baseline: 'Yes'; at 24 hour 'No'	Baseline: 'No'; at 24 hour 'No'
Nesiritide (1+ 0.01)	6	7	5	1	7	6
Nesiritide (2+0.005)	4	7	9	2	8	9
Nesiritide (2+0.01)	4	1	12	1	4	10

Intervention	Participants (Number)
	At 3 hour: Score 1	At 3 hour: Score 2	At 3 hour: Score 3	At 3 hour: Score 4	At 3 hour: Score 5	At 6 hour: Score 1	At 6 hour: Score 2	At 6 hour: Score 3	At 6 hour: Score 4	At 24 hour: Score 1	At 24 hour: Score 2	At 24 hour: Score 3	At 24 hour: Score 4
Nesiritide (1+ 0.01)	5	2	3	3	0	6	3	1	2	4	3	1	2
Nesiritide (2+0.005)	4	4	3	4	0	6	2	4	2	7	4	1	2
Nesiritide (2+0.01)	6	2	3	5	1	4	5	5	3	8	0	4	3

Intervention	ng/mL (Median)
	Preoperative baseline	1 hour after CICU admit	8 hours after CICU admit	24 hours after CICU admit
I- Nesiritide	0	1.2	0.5	0.2
II- Milrinone	0	2.7	0.5	1.5
III- Placebo	0	2.1	1.0	1.3

Intervention	mg/dL (Mean)
	Serum creatinine at baseline	Serum creatinine at 24 hours	Serum creatinine at 48 hours
Nesiritide	1.3	1.3	1.3
Nitroglycerin	1.3	1.4	1.4

Intervention	ng/mL (Mean)
	Cystatin-C at Baseline	Cystatin-C at 24 Hours	Cystatin-C at 48 Hours
Nesiritide	1332	1475	1449
Nitroglycerin	2026	3108	2739

Intervention	mL (Mean)
Low Dose Dopamine	4526.0
Placebo	4659.9
Low Dose Nesiritide	5177.2

Intervention	units on a scale * hours (Mean)
Low Dose Dopamine	4935.8
Placebo	4997.6
Low Dose Nesiritide	4831.4